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Schizophrenia (SZ) is a devastating mental illness characterized by complicated 
pathophysiology. Adenosine theory was proposed recently and showed the potential to 
combine classic theories into one common pathway. It is hypothesized that the 
reduction of adenosinergic activity in CNS could serve as a possible common 
explanation for the alterations of dopaminergic and glutamatergic neurotransmission in 
SZ. Based on previous reports and preliminary data, adenosine signaling might be an 
interesting and meaningful target to study. This dissertation thus was dedicated to test 
adenosine theory and to explore its clinical significance in SZ. 
This dissertation consists of four parts. First, we tested if levels of analytes in 
adenosine signaling was altered in SZ patients. We observed significant level changes 
of adenosine, adenosine deaminase (ADA) and inosine in SZ patients. We also 
observed disrupted connections between adenosine and ADA in SZ patients when 
comparing with that in controls. Second, we tested if such deficits could be affected by 
antipsychotic treatments. In this part results implied that antipsychotics could have an 
impact on adenosine signaling. However, treatments cannot fully restore the altered 
levels of those analytes. Third, we tested associations between the adenosine signaling 
within purine pathway and with other important biochemical pathways in SZ pathology. 
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Xiang Zhou 
University of Pittsburgh, 2018 
University of Pittsburgh, 2018
 
 V 
A homeostasis imbalance of purine pathway were observed and the pathway was 
shifted towards the direction in favor of uric acid production. We also observed that 
reduced uric acid levels were linked to elevated levels of oxidative stress. For inter-
pathway correlations, we found significant correlations between adenosine levels and 
red blood cell membrane defects. We also observed inverse correlation between 
adenosine and homovanillic acid. Fourth, significant correlations were observed 
between analytes’ levels and positive symptoms as well as between analytes’ levels and 
global functioning scale. Findings here suggested that levels of adenosine and ADA in 
plasma and CSF may have important clinical implications. 
In summary, adenosine signaling deficits were suggested to be present in SZ 
patients and can be linked to classical SZ theories. Also, findings revealed the clinical 
significance of adenosine signaling and may shed light on the endeavors for new 
antipsychotics R&D. 
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1.0  INTRODUCTION 
1.1 SCHIZOPHRENIA AND CLASSICAL THEORIES IN EXPLAINING ITS 
PATHOLOGY 
Schizophrenia (SZ) is a debilitating mental disorder with a global prevalence from 0.4% to 0.7% 
(Bhugra 2005, van Os and Kapur 2009). The active phase of SZ typically begins in late 
adolescence or early adulthood and lasts a long time to senior ages (National Institute of Mental 
Health 2016, American Psychiatric Association 2013). Common symptoms fall into three 
major categories: positive, negative and cognitive. Positive symptoms are those that are present 
in people with schizophrenia and that normal people do not experience. They include delusions, 
hallucinations, disordered thoughts, movements and behaviors. Negative symptoms are deficits 
or reduction in normal emotional responses, experiencing of pleasure, motivation and verbal 
productivity. They include “flat affect” (reduced expression of emotions via facial expression, 
gesture or voice tone); anhedonia (reduced feelings of pleasure in everyday life); motivation 
deficits such as difficulty beginning and sustaining activities and alogia (reduced speaking and 
reduced content of speech). Cognitive symptoms refer to deficits in cognitive abilities including 
executive functioning, immediate and sustained attention and working memory. It is 
undeniable that SZ imposes a massive personal and economic burden to the individuals with 
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schizophrenia, their families and society. Social problems caused by SZ, such as homelessness, 
long-term unemployment and poverty are common (American Psychiatric Association. 2013, 
Foster et al. 2012).  
The study of SZ’s etiology and symptomatology has been pursued for nearly a century. 
However, SZ is a disease of complicated pathology. In addition to its heterogeneous clinical 
presentation and course of illness, the nature and origin of the pathology is unclear and unlikely 
to be uniform. With regard to observed biochemical abnormalities, SZ has been attributed to 
multiple metabolic defects originating from different biochemical pathways. Previous studies 
have linked SZ to widespread structural and functional brain alterations, including multiple 
neurotransmitter pathway disruptions (Karam et al. 2010, Walsh et al. 2008, Brisch et al. 2014, 
Kerne, 2009), white matter changes (Kubicki et al. 2005, Lener et al. 2014) and prefrontal-
limbic network dysfunctions (Weinberger et al. 1992, Weinberger et al. 1988). Based on 
previous findings, there are four classical biochemical theories that aim to explain SZ’s 
pathology: Dopamine, glutamate, phospholipid and serotonin hypothesis (Table 1). However, 
none of them can fully explain SZ’s pathophysiology. While there are disparate biological 
findings and theories reported in SZ, accumulating evidence suggests that there might be up-
stream factors (Howes and Kapur, 2009). Alterations of these up-stream factors by SZ 
eventually lead to down-stream biochemical defects which have been reported that point to 
striatal dopamine hyperfunction (Meltzer and Stahl. 1976, Seeman. 1987), NMDAR 
hypofunction (Kim et al. 1980, Coyle. 1996, ,Moghaddam and Javitt, 2012), cerebral serotonin 
overdrive (Eggers. 2013) and increased lipolysis of cell membranes (Horrobin. 1998). 
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Table 1. Classical theories in explaining schizophrenia’s pathology 
Abbreviations: NMDAR = N-methyl-D-aspartate receptor; PET = positron emission 
tomography; SZ = schizophrenia; PLA2 = phospholipases A2; PNS = peripheral nervous 
system; CNS = central nervous system. 
1.2 NEW EMERGING HYPOTHESIS AND ADENOSINE SIGNALING 
Adenosine hypothesis of SZ was first proposed in 2006 and further developed recently (Lara 
et al. 2006, Boison et al. 2012). Specifically, the new hypothesis suggests that a specific 
dysfunction in the purinergic system would result in reduced adenosinergic activity (Figure 1) 
Theory References Claim Limitation 
Dopamine 
Meltzer and 
Stahl, 1976; 
Seeman, 1987; 
Howes and 
Kapur, 2009. 
A striatal hyperactivity of 
the dopaminergic signaling 
leads to SZ pathology and 
symptomatology. 
1. PET data have technical limitations. 
2. Improvement in psychosis without 
modulating dopamine system by 
antipsychotics such as LY2140023 
(NMDAR agonist). 
Glutamate 
Kim et al. 1980; 
Coyle, 1996; 
Moghaddam and 
Javitt, 2012. 
Reduced NMDAR activity 
on inhibitory neurons leads 
to the disinhibition of 
synaptic glutamate activity 
in the prefrontal cortex and 
causes SZ symptoms. 
1. Weak in correlating & explaining 
positive symptoms. 
2. Several subgroups of SZ patients are no 
responsive to NMDAR agonists. 
Lipid Horrobin, 1998 
Due to increased activity of 
PLA2, an increased break 
down of cell membranes in 
PNS and CNS causes SZ 
symptoms. 
1. Limited efficacy of lipid-modulating 
drugs on SZ symptoms. 
2. Weak in correlating & explaining 
negative symptoms. 
Serotonin Eggers, 2013 
Chronic and widespread 
stress-induced serotonergic 
overdrive in the cerebral 
cortex is the basic cause of 
the disease. 
1. Weak in correlating & explaining 
negative and cognitive symptoms. 
2. Second-generation antipsychotics on 
serotonin pathway are also affecting 
dopaminergic signaling. 
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in CNS, which could serve as a possible common explanation for the imbalance of 
dopaminergic and glutamatergic neurotransmission that is characteristic of SZ.  
There are two major sources of evidence to support the new emerging hypothesis. The 
first source of evidence comes from solid animal pharmacology data. Previous studies have 
revealed adenosine’s effect on monoamine pathways in the CNS (Matos et al. 2015, Pardo et 
al. 2012, Salmi et al. 2005). Specifically, activation of A2AR inhibits both NMDAR and D2Rs 
while activation of A1Rs inhibits D1Rs and enhances NMDARs. Those manipulations correlate 
with motor activity, learning and memory in animal models (Matos et al. 2015, Pardo et al. 
2012). The molecular basis of the adenosine-based manipulation on dopaminergic and 
glutamatergic neurotransmission has been summarized in Figure 2. On the other hand, however, 
there is no evidence that dopamine or other neurotransmitters can regulate adenosine levels in 
the CNS. 
The second source of evidence implies that the manipulation of adenosine signaling 
could have potential clinical significance in SZ pathology, as discussed below. First, 
augmentation of adenosine by pharmacologic inhibition of adenosine kinase (ADK), the key 
enzyme of adenosine clearance, exerts antipsychotic-like activity in mice (Shen et al. 2012). In 
contrast, overexpression of ADK in transgenic mice was associated with attentional and 
learning impairments which linked to SZ (Shen et al. 2012, Yee et al. 2007). Second, it is 
reported that atypical anti-psychotics can up-regulate adenosine receptors (A2AR) and improve 
sensory gating in SZ patients (Zhang et al. 2012). Third, one clinical study suggested that 
purinergic signaling modulator adjuvant therapy (allopurinol, xanthine oxidase inhibitor) is 
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more beneficial in SZ psychopathology in comparison with placebo, especially in the treatment 
of refractory positive symptoms (Brunstein et al. 2005). 
 
 
 
 
 
 
 
Figure 1. Reduced adenosine signaling and proposed underlying mechanisms of SZ 
pathophysiology. 
Figure 2. The molecular basis and pathways of adenosine-based manipulation of 
glutamatergic and dopaminergic neurotransmission in schizophrenia pathology. 
 
Abbreviations: D1Rs = dopamine 1 receptors; LTP = long-term potentiation; LTD = long-term 
depression; NMDAR = N-methyl-D-aspartate receptor; SZ = schizophrenia. 
Contents in green boxes refer to established relationships and contents in blue boxes refer to 
the postulated hypothesis. 
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Based on findings mentioned above, it is suggested that adenosine signaling might be 
an interesting target to study. Thus, a brief introduction about adenosine signaling is provided 
here. Adenosine is a purine nucleoside composed of a molecule of adenine that is attached to a 
ribose sugar molecule (ribofuranose) moiety via a β-N9-glycosidic bond (Morton and Judith. 
2012, Buckingham. 1987, Taylor and Francis. 2000). Adenosine may be formed intracellularly 
in both neuronal and glial cells (Latini and Pedata. 2001, Meghji et al. 1989) from degradation 
of adenosine monophosphate, and then exit via bi-directional nucleoside transporters, or 
extracellularly by the metabolism of released nucleotides (Zimmermann. 1996). In the brain, 
adenosine is an inhibitory neurotransmitter. This means, adenosine could act as a central 
nervous system (CNS) depressant. The increase of adenosine activity can lead to the decreased 
release and activity of other neurotransmitters such as dopamine and norepinephrine (Ferré et 
al. 1997, Burgdorf et al. 2001, Rongen et al. 1996), while no evidence showed that dopamine 
or norepinephrine can have an impact on adenosine levels or adenosine signaling activity in 
the brain. In normal conditions, adenosine promotes sleep and suppresses arousal (Basheer et 
al. 2004, Scammell et al. 2001, Gallopin et al. 2005). 
After being released from intracellular stores into circulation, adenosine is broken down 
to inosine by adenosine deaminase (ADA) which presents in both CNS and peripheral tissues 
(Lovatt et al. 2012). There are two recognized isoforms of ADA in the CNS: ADA1 and ADA2. 
The metabolism and physiological transportation of these two isoforms in the brain and CSF 
are still not clear. Since the ratio and distribution of these two isoforms in the brain are poorly 
studied, the Km of ADA for adenosine is in the range (depends on ratios of isoforms) of 25–
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150 µ M with a Vmax at 3.6 x 10-9 µM/s under normal adenosine concentration levels (Ford et 
al. 2000, Singh and Sharma. 2000). This Km is much higher than adenosine concentrations 
under normal physiologically condition which is below 1µ M (Conlay et al. 1997). Therefore, 
the reaction from adenosine to inosine via ADA might be substrate-limited. Currently, the full 
physiological role and regulation of ADA is not yet completely understood (Cristalli et al. 
2001). There are some evidence suggested that ADA can be regulated by cytokines through 
fine immunoregulatory mechanism of NF-kB signaling in leukocytes. Specifically, it is 
reported that interleukin-2 and interleukin-12 can up-regulate ecto-ADA and CD26 (a 
lymphocyte marker that can anchor ADA on the T cell surface) expression while interleukin-4 
led to down-regulation of lymphocyte surface ADA without modifying the level of CD26 
(Cordero et al. 2001, Wiginton et al. 1991). However, no evidence has linked adenosine, 
dopamine or any other neurotransmitters with the regulation of ADA expression or activity. 
Current assays on ADA (including the assay in this dissertation) was measuring on its activity 
which expressed by International Unit (I/U or U). One Unit is the amount of enzyme that 
catalyzes the reaction of 1 µmol of substrate per minute. The normal reference range of ADA 
activity is from 15.0-23.2 I/U in the plasma (Al-Shammary et al. 1993) and 0-9 I/U in the CSF 
(Corral et al. 2004). In peripheral tissues, both adenosine and its metabolite (inosine) can cross 
through the blood-brain barrier via purine transporters located on brain capillary endothelial 
cells (Cornford and Oldendorf. 1975, Pardridge. 2005). However, few studies have explored 
the relationship of metabolite and enzyme levels in the CNS versus peripheral tissues.                                                                     
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Adenosine signaling and adenosine receptors (ARs) have been well studied in past 
decades. All ARs subtypes (A1, A2A, A2B, and A3) are G-protein-coupled receptors. There are 
two major types of ARs (A1R and A2AR) enriched in the CNS. The A1 receptors couple to Gi/o 
and decrease adenylate cyclase levels, while the A2 receptors couple to Gs, which enhances 
adenylate cyclase activity. Many important biochemical processes are controlled by ARs and 
their subsequent regulation of adenylate cyclase, such as cell proliferations (Pardee. 1989, 
Stork and Schmitt. 2002, Igata et al. 2005, Granata et al. 2007), immune responses (Deaglio et 
al. 2007, Haskó & Cronstein. 2004, Sitkovsky and Lukashev. 2005, Haskó et al. 2008) and 
lipid metabolism (Bricker and Levey. 1972, Park et al. 2008, Koupenova et al. 2012, Guo et al. 
2012). However, the potential for adenosine signaling alterations in SZ patients, either in 
plasma or CNS, is still unclear today. Furthermore, as mentioned above, while atypical anti-
psychotics can up-regulate adenosine receptors (A2AR) and alleviate clinical symptoms, the 
clinical treatment effects on adenosine, inosine and ADA activity levels in SZ patients are still 
unknown and urgently need to be studied. Considering the new adenosine hypothesis that is 
introduced above, we believe that studying adenosine signaling in SZ pathology would be 
helpful in unveiling SZ’s pathophysiology and offering useful directions in developing new 
treatment strategies. 
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1.3 PURINE PATHWAY IN SCHIZOPHRENIA 
Biochemically, adenosine and its metabolites belong to a group of molecules referred to as 
purines. Adenosine signaling is a step in the process of in purine metabolism (Figure 3). Purines 
are critical in building up blocks of genetic codes and therefore the foundation of life, as 
represented by deoxyribonucleic acid (DNA). In other words, purines are central to the 
maintenance and reproducible existence of our nucleotide-protein system, which produces cells 
and tissues (Fredholm et al. 2010). According to the adenosine hypothesis, in SZ, adenosine 
signaling deficits are caused by a purine system dysfunction (Lara et al. 2006). Therefore, it 
would be interesting to study the relationship between a possible disturbance of the purine 
pathway and adenosine signaling in SZ. 
     The disturbance of the purine pathway in SZ was firstly reported in the 1950s (Kishimoto, 
1956). By using paper chromatography, Kishimoto found a significant difference in the 
absorbance of purines among individuals with SZ and normal control subjects both in serum 
and in brain specimen. Interestingly, our lab also found significant alterations of several purine 
metabolites in plasma among first-episode antipsychotic-naïve schizophrenia patient (FEANS) 
such as uric acid and xanthosine (Yao et al. 1998, Yao et al. 2010). However, adenosine 
signaling was not measured at that time; thus, the question of whether alterations of the purine 
pathway can cause the compensatory shift from adenosine to uric acid (and eventually lead to 
the adenosine signaling deficit) was not addressed in those studies. Therefore, it is proposed 
here that the addition of adenosine signaling as well as other metabolites (guanosine, guanine, 
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xanthine and hypoxanthine) into the model (Figure 3) would fill in an important part of the 
puzzle. 
      As mentioned above, our previous study showed a significant decrease of uric acid in 
the plasma of FEANS patients (Yao et al. 1998). Since uric acid is an important antioxidant 
and accounts for up to 65% of reactive oxygen species (ROS) clearance in the body  (Wayner 
et al. 1987, Miller et al. 1993), it is hypothesized that the uric acid deficit is due to the increase 
of ROS levels and the breakdown of antioxidant defense system (AODS). The increase of ROS 
levels and the breakdown of AODS reflects an elevated level of oxidative stress in SZ. In fact, 
based on previous publications, oxidative stress plays a significant role in SZ pathology. 
Several published studies indicate that there is an increased level of major oxidative stress 
markers (Boscovic et al. 2011, Emiliani et al. 2014, Akyol et al. 2002) and a breakdown of the 
antioxidant system (Dadheech et al. 2006, Yao et al. 2011, Mukherjee et al. 1996, Ranjekar et 
al. 2003) in SZ patients. Clinical studies also successfully correlate oxidative stress to the 
positive (Pavlović et al. 2002, Fendri et al. 2006), negative (Gunes et al. 2017, Wood et al. 
2009) and cognitive symptoms (Maas et al. 2017, Hardingham and Do. 2016) in SZ. These 
findings motivated us to explore the correlation of oxidative stress with purine pathway 
alterations (especially the reduction of uric acid) in SZ. In summary, we hypothesize that 
oxidative stress causes uric acid reduction and leads to a homeostatic imbalance in the purine 
pathway which eventually results in adenosine signaling deficits.  
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1.4 LIPID THEORY AND ADENOSINE SIGNALING 
As a major component of myelin, phospholipids play a crucial role in maintaining myelinated 
neuronal axons. Several studies have shown that at least 70% dry mass of both CNS and PNS 
myelin is formed by lipids (Baumann and Pham-Dinh, 2001, Chrast et al. 2010). The classic 
lipid theory of SZ claims that an increased breakdown of neuron cell membranes in PNS & 
CNS results in SZ symptoms. Specifically, previous findings (Gattaz et al. 1990, Pettegrew et 
al. 1991, Horrobin et al. 1991, Noponen et al. 1993) suggested that in both CNS and peripheral 
tissues, SZ patients have an increased breakdown of membrane phospholipids due to increased 
PLA2 activity. These observations have led to the hypothesis that the increased breakdown of 
phospholipids may cause dyslipidemia, impair myelinated neurons and contribute to SZ 
pathology. Currently there are few studies that have compared the levels of membrane 
Abbreviations: NP = nucleoside phosphorylase; DA = deaminase; XO = xanthine oxidase; 
XMP = xanthosine monophosphate.  
Figure 3.  Purine pathway metabolism.  
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phospholipids, the resulting free fatty acids (FFAs) after breakdown, cholesterol and 
triglycerides all together in SZ patients versus normal controls. Therefore, an investigation of 
lipid metabolism in SZ is proposed here to investigate the biochemical causes of dyslipidemia 
in SZ pathology. 
On the other hand, adenosine’s role in mediating lipid metabolism--especially in 
lipolysis and insulin activity--has been well-studied in animal models. ARs are present within 
pancreatic islets and are suggested to mediate insulin secretion. Specifically, low adenosine 
concentration in rat islets can decrease glucose-induced insulin secretion while elevated 
concentration can increase secretion. This regulation is via A1 receptor (Szkudelski and 
Szkudelska. 2015, Campbell et al. 1982). Over-expression of adipocyte A1 receptor in 
transgenic mice prevented the occurrence of insulin resistance induced by a high fat diet (Dong 
et al. 2001). In rat fat cells, adenosine increased insulin activity, glucose transport maximal 
response and fatty acid synthesis (Joost and Steinfelder. 1982, Koupenova et al. 2013) via the 
A1 receptor. Also, adenosine enhanced effect of insulin on the inhibition of lipolysis via the A1 
receptor (Schwabe et al. 1974, Johansson et al. 2008). The mechanism by which A1 receptor 
enhances insulin sensitivity is mediated by the activation of cAMP-dependent protein kinase 
(Koupenova et al. 2013). These findings suggest that adenosine may play a critical role in lipid 
metabolism.  
Based on these findings, the hypothesis was made that decreased adenosine signaling 
in SZ might cause increased lipolysis of membrane phospholipids and the observed 
dyslipidemia. A recent study found that dyslipidemia is linked to a down-regulated adenosine 
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signaling (Liu et al. 2014). In Liu’s study, abnormal lipid metabolism induces down-regulation 
of ATP synthase via the Akt phosphorylation pathway in a high-fat diet mouse model. In 
human studies, despite numerous publications that implicate a disturbance of lipid metabolism 
(such as increased membrane lipolysis) in SZ patients, few studies have demonstrated 
correlation between lipid metabolism and adenosine signaling. Therefore, partial support for 
the lipid theory of SZ would be provided by investigation of the correlation of membrane 
lipolysis with adenosine signaling among individuals with SZ.  
1.5 DOPAMINE THEORY AND ADENOSINE SIGNALING 
After more than fifty years’ revision, the current dopamine theory is now depicting a 
complex picture for schizophrenia. It links pregnancy complications, stress, drug use and genes 
to an increased striatal dopaminergic function (Howes & Kapur. 2009). With regard to 
dopamine metabolism, we are interested in dopamine’s two major precursor amino acids 
(phenylalanine and tyrosine), and also its major metabolite--homovanillic acid (HVA). 
Phenylalanine and tyrosine are precursor amino acids in the biosynthesis of dopamine. 
In the brain, the enzyme phenylalanine hydroxylase (PAH) converts phenylalanine to tyrosine. 
Previous findings (Table 2) implicate a dysregulation of dopamine synthesis in SZ. Genetic 
studies have also suggested that PAH gene polymorphisms confer susceptibility to 
schizophrenia (Talkowski et al. 2009) and modify features of psychotic disorders (Bergen et 
al. 2010). On the other hand, HVA is the final product of dopamine metabolism. Plasma HVA 
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has long been believed to be a peripheral index of subcortical dopaminergic activity (Pickar et 
al. 1988, Beuger et al. 1996). Since the dopamine theory suggests an increased striatal 
dopaminergic synthesis and transmission in SZ patients (Lindström et al. 1999, Kegeles et al. 
2010), it is expected that plasma HVA levels will be increased in SZ patients. In fact, a higher 
level of plasma HVA has been found in prodromal states of SZ (Sumiyoshi et al., 2000). 
Furthermore, significant correlations between plasma HVA level and SZ positive and negative 
symptoms have been reported (Pickar et al. 1986, Davis et al. 1985, Joel et al. 1993). These 
findings have made HVA as well as phenylalanine and tyrosine interesting targets to study. 
As mentioned in section 1.2, adenosine signaling has an inhibitory effect on DRs that 
are predominantly distributed in the striatal area (Missale et al. 1998). To test the adenosine 
hypothesis, we would like to investigate the hypothesized correlation of adenosine signaling 
with indicators of dopamine metabolism dysfunction in SZ pathology. Specifically, it is 
hypothesized that adenosine signaling deficits will correlate with increased levels of 
phenylalanine, tyrosine and HVA in SZ patient plasma. 
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Table 2. Summary of findings in phenylalanine and tyrosine assays in schizophrenia 
Abbreviations: Phe = phenylalanine; Tyr = tyrosine; SZs = schizophrenia patients; HCs = 
healthy control subjects. 
1.6 DISSERTATION DESIGN 
This dissertation is designed to test the adenosine hypothesis mentioned above (Lara et 
al. 2006, Boison et al. 2012) through an analytical approach using clinical samples. The central 
hypothesis is: Due to a purinergic signaling homeostatic imbalance, adenosine signaling 
deficits are present in SZ patients and correlate with clinical psychopathology in these 
Author Year Samples Findings Implication Limitation 
Okusaga et al 2014 
1000 SZs, 
950 HCs 
Phe increased 
in SZ plasma; 
Phe/Tyr ratio 
increased 
Results suggest an abnormal 
PAH function caused by immune 
activation and oxidative stress. 
High Phe in plasma could result 
in intellectual disability in SZ. 
Antipsychotic 
medication; 
samples are 
collected without 
fasting protocol 
Poisner 1960 
40 SZs, 
15 HCs 
Phe increased 
in SZ serum 
High Phe level is related to 
mental illness. 
Antipsychotic 
medication 
Bjerkenstedt 
et al 
1985 
37 SZs, 
65 HCs 
Phe increased 
in SZ plasma 
The disruption of monoamine 
neurotransmitter synthesis is 
suggested. 
Combined drug 
naïve group with 
medication group 
Tortorella  
et al 
2001 
11 SZs, 
11 HCs  
Tyr increased 
in SZ plasma 
Indicating that PAH activity may 
be inhibited in the early-onset 
patients with schizophrenia. 
Small sample size;  
Antipsychotic 
medication 
Rao et al 1992 
77 SZs, 
90 HCs 
Phe increased 
in SZ plasma 
As Tyr competes with 
tryptophan and Phe to get into 
the brain, findings may imply 
more Phe gets into the brain. 
Antipsychotic 
medication 
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individuals with SZ. Specifically, it is proposed that adenosine signaling deficits will correlate 
with hyperdopaminergic signaling, increased membrane lipolysis and clinical symptomatology 
in SZ patients. Second, it is proposed that antipsychotic treatment will be associated with at 
least partial restoration or normalization of the adenosine signaling in SZ patients. This 
hypothesis would be supported by evidence for each of four specific aims: 
Aim 1: Test if adenosine signaling deficits present in SZ patients. This aim will be addressed 
in Chapter 2. 
Aim 2: Test if antipsychotics can affect and restore back adenosine signaling. This aim will be 
addressed in Chapter 3. 
Aim 3: Test correlations of adenosine signaling deficit within purine pathway and with classic 
theories in SZ pathology. In this dissertation, we will test relationships between (A) adenosine 
signaling and lipid theory; (B) adenosine signaling and dopamine theory. This aim will be 
addressed in Chapters 4-6. 
Aim 4: Test if adenosine signaling correlates with SZ symptomatology. This aim will be 
addressed in Chapter 7. 
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2.0  ADENOSINE SIGNALING DEFICITS IN SCHIZOPHRENIA PATIENTS 
2.1 BACKGROUND 
In this chapter, we tested if adenosine signaling deficits are present in SZ patients as 
hypothesized in the adenosine theory. Target analytes that we measured are adenosine, ADA 
and inosine. The ADA metabolizes adenosine to inosine in both CNS and peripheral tissues. 
Currently no research was performed measuring adenosine, ADA activity and inosine levels 
all together in SZ patients. However, we did find genetic studies showed lower frequency of 
the low activity ADA allelic variant in SZ patients (Dutra et al., 2010). It has also been reported 
that in chronic SZ patients, there is an increased serum ADA activity (Brunstein et al., 2007). 
These findings implied that an increased ADA activity might also be found in our study at least 
in peripheral tissues for the SZ group.  
This chapter also serves as the aim 1 of the dissertation. This aim is further supported 
by three sub-aims. Results & discussion are based on the flow of following sub-aims: 
Aim 1a. Test if peripheral tissue levels of analytes in adenosine signaling can 
predict those levels in the CNS. Here, we checked correlations of each analyte in adenosine 
signaling between cerebrospinal fluid (CSF) levels and plasma levels. Both healthy control 
(HC) group and SZ group were involved in this experiment. 
Aim 1b. Test if there is an illness effect on adenosine signaling. For this aim, we 
compared adenosine, inosine and ADA activity levels between chronic off-treatment SZ patient 
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group and HC group. Group information is illustrated in experimental procedure section. 
Comparisons were made both in CSF and in plasma. We also compared correlations of 
adenosine and its major metabolizing enzyme (ADA) between off-treatment SZ group and HC 
group.  
Aim 1c. Test if adenosine signaling deficit is a trait-like feature of SZ. Traits here 
are representing characteristic alterations of SZ that are consistent and long lasting. Unlike 
traits, which are stable characteristics, states are temporary level changes that depend on a 
person's situation and treatments at a particular time. To test this aim, we compared adenosine, 
inosine and ADA activity levels among first-episode drug naive schizophrenia patient (FEANS) 
group, disease control (DC) group and HC group. We also compared correlations of adenosine 
and ADA among these three groups.  
It is predicted that adenosine levels will be reduced in the SZ patients, and that this 
reduction will be associated with increased activity of its major metabolizing enzyme (ADA). 
Consequently, an increased product (inosine) level should be observed. Also, it is predicted 
that we will observe that the correlation between adenosine and ADA breaks down in SZ 
patients. Overall, we predict adenosine signaling deficits are present in SZ patients. 
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2.2 EXPERIMENTAL PROCEDURES 
2.2.1 Clinical design 
1. Chronic SZ and control groups. Twenty-four SZ patients were from clinical services of 
the VA Pittsburgh Healthcare System (VAPHS). All procedures were approved by the VAPHS 
Highland Drive Institutional Review Board. After providing informed consent for their 
participation, patients were recruited after having had at least two years of treatment on 
antipsychotics. Diagnostic assessments and clinical symptom ratings were performed by 
experienced research clinicians. Patients were on stable doses of antipsychotics and voluntarily 
withdrawn from the treatment for two month. Both CSF and plasma samples were collected 
two months after the antipsychotic withdrawal date. In addition, 10 age-, race-, BMI- and 
gender-matched HC subjects were also recruited for comparison. The demographic table of 
subjects is shown below (Table 3). 
Table 3. Demographic table of recruited subjects in chronic SZ and control groups 
 
 
 
 
 
 
a Male/Female. b Caucasian / African American / Pacific Asian / others.  
Abbreviations: HC = healthy controls; Off-treatment = chronic schizophrenia patients that are 
withdrawn from antipsychotics for two months; FEANS = first episode antipsychotic naïve 
  HC Off-treatment 
Numbers  10 24 
Gender a 6/4 15/9 
Age  45.4 ± 7.8 46.9 ± 8.9 
BMI 26.7 ± 5.2 28.0 ± 6.6 
Race b 7/3/0/0 16/7/1/0 
 20 
schizophrenia patients. Note: age and BMI data are expressed in mean ± standard deviation. 
 
2. FEANS and control groups. Forty SZ patients were recruited during their first episode of 
psychosis after they provisionally met Diagnostic and Statistical Manual of mental disorders 
(DSM)-IV criteria for schizophrenia, schizophreniform, or schizoaffective disorder based on 
the Structured Clinical Interview for DSM Disorders (SCID). Diagnostic assessments and 
clinical symptom ratings were performed by experienced research clinicians. Initial and follow-
up diagnoses were confirmed at diagnostic conferences attended by research faculty and staff, 
and chaired by an experienced psychiatrist. Blood samples were collected and clinical 
symptoms were evaluated prior to initiation of clinicians’ choice of antipsychotic agents. In 
addition, 52 age-, race-, BMI- and gender-matched HC subjects and 24 patients with other 
psychiatric disorders (including bipolar disorder and major depression) were also recruited for 
comparison. The demographic table of subjects is shown below (Table 4).  
 
Table 4. Demographic table of recruited subjects in FEANS and control groups 
a Male/Female. b Caucasian / African American / Pacific Asian / others.  
Abbreviations: HC = healthy control subjects; DC = disease controls; FEANS = first episode 
antipsychotic naïve schizophrenia patients. Note: age and BMI data are expressed in mean ± 
  HC DC FEANS 
Numbers  52 24 40 
Gender a 31/20 13/11 26/14 
Age  26.3 ± 7.4 26.9 ± 9.9 22.7 ± 8.1 
BMI 25.2 ± 4.4 25.2 ± 6.9 23.3 ± 5.3 
Race b 34/10/3/4 17/5/1/1 20/16/2/2 
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standard deviation; in HC group, one subject is missing sex and race information. Three 
subjects in FEANS group and one in DC group are missing BMI data due to missing 
height/weight values. 
2.2.2 Sample preparation 
CSF and blood samples were collected from subjects mentioned above. None of the subjects 
were currently on anticoagulants. Plasma aliquots were collected from blood samples after 
centrifugation, and then transferred to 2 mL tubes. All samples were stored in -80oC freezers. 
QC (quality control) samples were made from the sample pools in each group, respectively. 
All samples used in this dissertation went through these preparation procedures. 
 
2.2.3 Enzyme-linked immunosorbent assay 
Adenosine and inosine levels were assayed by using enzyme-linked immunosorbent assay 
(ELISA) kits from Biovision (K327 & K712). For adenosine assay kit, linear standard curve 
range is from 0.01-0.5 µM. The Lower Limit of Quantificantion is 0.0025 µM. Intra assay 
percentage of CV is below 2.0% and inter assay percentage of CV is below 3.0%. For inosine 
assay kit, linear standard curve range is from 0.1-5 µM. The Lower Limit of Quantificantion is 
0.04 µM. Intra assay percentage of CV is below 2.0% and inter assay percentage of CV is 
below 2.5%. ADA activity levels were assayed by using ELISA kits from Diazyme (DZ117A-
K). For ADA assay kit, linear standard curve range is from 0-200 I/U. The Lower Limit of 
Quantificantion is 0.075 I/U. Intra assay percentage of CV is below 4.5% and inter assay 
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percentage of CV is below 5.0%. Each assay was conducted by strictly following the protocol 
that was recommended by the kit. Readings were obtained from a PerkinElmer micro plate 
reader (Wallac 1420). Adenosine and inosine data were read at Ex/Em = 535/587 nm 
(fluorometric method) while ADA activity data were read at 550 nm (colourimetric method). 
Each sample was tested in duplicates and QCs were used to check the differences between 
plates.  
2.2.4 Data analysis 
Data analysis for this chapter followed the flow chart below (Figure 4). In brief, data in VA 
chronic SZ & control groups were used for correlation analyses between CSF and plasma. For 
each single analyte, each subject in this group had matched CSF and plasma data; therefore, 
correlations could be estimated within subjects (i.e. each subject served as its own control). For 
the comparisons between groups, analysis of variance (ANOVA) tests were used to test 
differences in analyte levels across HCs, DCs and FEANS. Follow-up post-hoc tests were 
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corrected by Bonferroni corrections. T-tests were used to compare the chronic off-treatment 
group and the HC group. For comparison of correlations of adenosine and ADA between 
groups, Pearson correlation coefficients were used to test the association. Fisher’s r to z 
transformation was applied and correlation coefficients of adenosine vs ADA among different 
groups were compared. All data and results were checked for skewness by quantile-quantile 
plot. All tests were two-tailed. 
 
 
 
2.3 RESULTS 
2.3.1 Correlations between CSF and plasma analyte levels within subjects 
Consistent with expectation, significant correlations (p < 0.05) were observed between CSF 
and plasma analyte levels in most 
cases (Figure 5). The correlation of 
CSF with plasma ADA levels in the SZ group only showed a trend for significance (p < 0.1). 
Also, with the exception of the CSF/plasma association for ADA levels in SZ, significant 
correlations were found for both HC and SZ groups.  
 
 
Figure 4.  Data analysis flow chart for chapter 2.  
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2.3.2 Comparison of CSF analytes’ levels between HC group and chronic SZ off-
treatment group 
In CSF samples, significant reduction of adenosine and inosine levels were observed in off-
treatment SZ patients in comparison with HCs. As expected, a significant increase of ADA 
activity levels was observed in off-treatment SZ patients when compared with HCs (Figure 6). 
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Figure 5.  Correlations between CSF and plasma levels of adenosine, ADA activity and 
inosine in HC and chronic SZ groups.  
Abbreviations: ADA = adenosine deaminase; HC = healthy controls; SZ = schizophrenia patients. 
p = 0.00028 
  
Plasma 
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2.3.3 Comparison of plasma analytes’ levels between HC group and chronic SZ off-
treatment group 
We then compared these analytes’ levels between HC group and chronic SZ off-treatment 
group. In plasma samples, a significant reduction levels of adenosine was also observed in off-
treatment SZ patients. However, no significant change was found between the off-treatment 
group and the HC group with regard to ADA activity and inosine levels (Figure 7). 
 
Figure 6.  Comparisons of CSF adenosine, ADA activity and inosine levels in HC group 
and SZ off-treatment group  . ADA = adenosine deaminase; HC = healthy controls. Units: 
adenosine and inosine are in µM, ADA is in I/U. 
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2.3.4 Correlations between adenosine and ADA in HC group and SZ off-treatment 
group 
As expected, significant inverse correlations were observed between adenosine and ADA in 
HC group (Figure 8). In contrast, a highly disrupted correlation between adenosine and ADA 
was found in the off-treatment SZ group. Instead of significant negative correlations of 
adenosine with ADA shown in the HC group, there was a trend (p < 0.07) for a positive 
correlation of adenosine with ADA in the off-treatment SZ group on CSF measures. No 
significant correlation was observed between adenosine and ADA in the off-treatment SZ 
group on the plasma measures (Figure 8). Fisher’s z test showed a significant difference of 
correlation coefficients between HC and off-treatment groups in the CSF samples (z = 2.94, p 
= 0.0033) but not in the plasma samples (z = 1.94, p = 0.0524). 
Figure 7.  Comparisons of plasma adenosine, ADA activity and inosine levels in HC group 
and SZ off-treatment group.  
Abbreviations: ADA = adenosine deaminase; HC = healthy controls. Units: adenosine and inosine 
are in µM, ADA is in I/U. 
 
 28 
 
 
 
 
 
 
 
 
 
 
 
  
 
2.3.5 Comparisons of plasma analyte levels among HC group, DC group and FEANS 
group 
As with the findings in 2.3.3, significantly lower adenosine plasma levels were observed in the 
FEANS group when compared with the HC and DC groups. However, no significant changes 
Figure 8.  Correlations between adenosine and ADA in HC group and in off-
treatment SZ group.  
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of ADA activity and inosine levels were observed among these three groups (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.6 Correlations between adenosine and ADA among HC, DC and FEANS groups 
Finally, we tested correlations between adenosine and ADA among the HC, DC and FEANS 
groups. Significantly inversed correlations of adenosine with ADA in the HC and DC groups 
were observed. In contrast, no significant correlations were observed between adenosine and 
Figure 9. Comparisons of plasma analytes’ levels among HC, DC and FEANS groups.  
Abbreviations: ADA = adenosine deaminase; HC = healthy controls; DC = disease controls. 
Units: adenosine and inosine are in µM, ADA is in I/U. 
p:  *  = 0.0003 
** = 0.0039 
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ADA for the FEANS group (Figure 10). However, Fisher’s z test did not show significant 
difference of correlation coefficients between HC and FEANS groups (z = -0.58, p = 0.5619) 
or DC and FEANS groups (z = -1.72, p = 0.0854). 
 
 
 
2.4 DISCUSSION 
From results in 2.3.1 we observed significant correlations (with a single exception, i.e. and 
association at a trend level) between CSF and plasma analyte levels in both HC group and SZ 
group. This finding would suggest that peripheral tissue adenosine, ADA activity and inosine 
levels can serve as indicators of CNS adenosine, ADA activity and inosine levels. One previous 
study assayed the ADA activity in CSF and in plasma simultaneously in order to help to 
diagnose tuberculous meningitis and they found both absolute CSF ADA activity levels and 
Figure 10.  Correlations between adenosine and ADA among HC, DC and FEANS groups.  
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the ratio of CSF to plasma ADA activity levels could distinguish the disease group from the 
control group (Donald et al. 1986). To our knowledge, no other study has systematically 
correlated adenosine signaling in CNS with that in the peripheral tissues.  
As predicted, significantly lower adenosine levels and higher ADA activity levels in 
the CSF of chronic off-treatment SZ patients were observed. These findings suggested that 
there is an illness effect on adenosine signaling in the CNS in SZ patients compared with HC 
subjects. Reduction of adenosine levels may result from increased metabolizing enzyme (ADA) 
activity, suggesting an increased breakdown of adenosine by ADA. However, the observation 
of significantly lower metabolite (inosine) levels is not consistent with the prediction. An 
increased breakdown of adenosine should have yielded more inosine, yet such increase was 
not observed. We hypothesized that it may be due to an increased activity of nucleoside 
phosphorylase and increased production of hypothanxine and the following metabolites on the 
purine pathway. This hypothesis was tested in Chapter 4. Significantly lower adenosine levels 
in plasma indicated that the illness effect on adenosine signaling in CNS can also be found in 
peripheral tissues. The unchanged plasma inosine levels may also be due to the increased 
activity of nucleoside phosphorylase and increased production of hypothanxine and the 
following metabolites on purine pathway. With regard to ADA activity, there are two possible 
reasons for failure to observe a significant change in plasma ADA activity in the chronic off-
treatment SZ group. First, it may be due to the limitation of sample size (n = 24), given that we 
observed a trend for higher ADA levels in the off-treatment SZ group as compared with the 
HC group (p = 0.082). Secondly, it may imply that peripheral measures are not as sensitive to 
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an illness effect on ADA activity as are CSF levels. Further studies are required to investigate 
CNS vs peripheral tissue ADA activity differences as well as to explore possible underlying 
mechanism (s). 
For the correlation between adenosine and ADA, we found that both in CSF and plasma 
samples, adenosine levels inversely correlated with ADA levels in control subjects. This 
finding is consistent with our expectation, as ADA is the major metabolizing enzyme of 
adenosine. The significant correlation revealed that in normal condition, enzyme (ADA) 
activity is tightly connected to the precursor (adenosine). However, in SZ patients, we found 
evidence for highly disrupted connections between adenosine and ADA. Whereas there were 
significant inverse ADA/adenosine correlations for the HC group in both CSF and plasma, 
there was a trend for a positive correlation in the CSF of the chronic off-treatment SZ group. 
Furthermore, there was no significant plasma ADA/adenosine correlation for the chronic off-
treatment SZ group. As is illustrated in the introduction section, the reaction from adenosine to 
inosine via ADA might be substrate-limited, which explained the lack of adenosine-ADA 
association by the reduced levels of substrates. Therefore, it is suggested that adenosine 
signaling is disrupted by SZ in both CNS and peripheral tissues. 
Significantly lower plasma adenosine levels in the FEANS group were observed and 
suggested that the potential adenosine signaling deficits may exist at the early course of the 
disease. Compared with findings in section 2.3.2 & 2.3.3, no significant differences in analyte 
levels were observed between the chronic off-treatment SZ group and the FEANS group. This 
suggested that the exposure & ‘left-over’ effect of the treatment did not play a significant role 
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here. Thus, these findings would suggest that CSF adenosine and ADA levels may serve as 
potential biomarkers of SZ and that these deficits may be trait-like features of SZ.  
It is important to note that in both the HC and DC groups, adenosine levels inversely 
correlated with ADA levels – a finding that in consistent with results in 2.3.4. This finding 
supports the notion that in the normal condition, enzyme (ADA) activity is tightly connected 
to the precursor (adenosine). We also observed a disrupted correlation between adenosine and 
ADA in the FEANS group; however, this disturbance was not as severe as that observed in 
chronic off-treatment SZ group as being supported by Fisher’s z test results. These observations 
imply that adenosine signaling may start to get disrupted early in the course of the disease and 
that such alteration exacerbates as the disease progresses. 
2.5 CONCLUSIONS 
1. Within subjects, significant correlations were observed in most cases between CSF and 
plasma analyte levels in both SZ group and HC group. These significant correlations indicated 
that peripheral tissue levels of adenosine signaling indices could serve as important indicators 
of adenosine signaling in the CNS. 
2. Significant decreased adenosine levels and significant increased ADA activity levels were 
revealed both in chronic off-treatment SZ group and FEANS group when compared with 
control groups, which suggested that there might be an adenosine hypofunction in the 
schizophrenia pathology. According to these findings, adenosine levels in CSF & plasma and 
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ADA activity levels in CSF may serve as potential biomarkers for SZ. 
3. Significantly reduced CSF levels and insignificantly changed plasma levels of inosine are 
not coherent with our original prediction. We think it might be caused by increased activity of 
nucleoside phosphorylase and increased production of hypothanxine & following metabolites 
in SZ pathology.  
4. Significant correlations between precursor (adenosine) and its major metabolizing enzyme 
(ADA) were observed in control groups, indicating tight connections between adenosine and 
ADA under normal condition. However, such tight connections were lost in SZ patients. 
Insignificant correlations were observed in both FEANS group and chronic off-treatment SZ 
group, implying the disruption of the adenosine signaling by SZ. Interestingly, a more disrupted 
correlation between adenosine and ADA were found in chronic off-treatment SZ group as 
compared with that in FEANS group, which implied that the disturbance of adenosine signaling 
begins at the early course of disease and exacerbates as disease progresses.   
Overall, in this chapter, alterations of levels and breakdown of connections between 
analytes in adenosine signaling were observed and adenosine signaling deficits were suggested 
in SZ patients. Such deficits tend to be trait-like features of SZ according to the data in this 
chapter.  
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3.0  TREATMENT EFFECT ON ADENOSINE SIGNALING 
3.1 BACKGROUND 
In this chapter, we tested if adenosine signaling can be affected by antipsychotics. As 
mentioned in the introduction section, activation of adenosine receptors would have inhibitory 
effect on DRs. Adenosine agonists produce similar pharmacological effects as dopamine 
antagonists (Ferré.1997). Therefore, we tested if dopamine blocker could restore adenosine 
signaling by inhibiting dopaminergic signaling. Antipsychotics used for this study are 
haloperidol and risperidone which belong to first- and second-generation antipsychotics, 
respectively. The mechanism of action of most first- and second-generation antipsychotics is 
post-synaptic blockade of brain D2 receptors (Jibson. 2016). Most second-generation 
antipsychotics differ from first generations pharmacologically in that they also bind to 5-HT2 
receptors. Since interactions between serotonin receptors and ARs are still not clear at current 
stage, it would be interesting to explore the potential differences between first- and second-
generation antipsychotic effects on adenosine, ADA, and inosine levels in SZ patients. 
This chapter also serves as the aim 2 of the dissertation. This aim is further supported 
by two sub-aims. Results & discussion are based on following sub-aims: 
Aim 2a. Test if antipsychotics can affect adenosine signaling. Test if the treatment 
effect were different between CNS and peripheral tissues. Here we were using chronic on-
treatment SZ patient CSF & plasma samples. We made comparisons between on-treatment SZ 
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group and off-treatment SZ group within subjects. HC group data that were collected from 
Chapter 2 were also used as reference.  
Aim 2b. Test short- vs long-term treatment effect in longitudinal study. To test this 
aim, we compared adenosine, inosine and ADA levels among antipsychotic naïve baseline and 
follow-up time points (1M, 6M and 12M) after treatments. Moreover, we also compared 
correlations between precursor (Adenosine) and its major metabolizing enzyme (ADA) in 
baseline and all time points. 
We were predicting that antipsychotics can affect and restore back adenosine signaling. 
Specifically, we predicted that treatment will increase levels of adenosine and inosine. Also, 
ADA levels will be reduced back to normal levels. The broken correlations between adenosine 
and ADA in the baseline could be normalized (or partially normalized) after the treatment. 
3.2 EXPERIMENTAL PROCEDURES 
3.2.1 Clinical design 
1. Chronic SZ and control groups. Twenty-four SZ patients were recruited from clinical 
services of the VA Pittsburgh Healthcare System (VAPHS). All procedures were approved by 
the VAPHS Highland Drive Institutional Review Board. After providing informed consent for 
their participation, patients were recruited after having had at least two years of treatment on 
antipsychotics. Diagnostic assessments and clinical symptom ratings were performed by 
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experienced research clinicians. Patients were on stable doses of antipsychotics and voluntarily 
withdrawn from the treatment for two month. Both CSF and plasma samples were collected 
before and two months after the antipsychotic withdrawal date. The demographic information 
of on-treatment SZ group has been shown in table 3. In addition, 10 age-, race-, BMI- and 
gender-matched HC subjects were also recruited for comparison.  
2. FEANS baseline, follow-up time points and control groups. Forty SZ patients were 
recruited during their first episode of psychosis after they provisionally met Diagnostic and 
Statistical Manual of mental disorders (DSM)-IV criteria for schizophrenia, schizophreniform, 
or schizoaffective disorder based on the Structured Clinical Interview for DSM Disorders 
(SCID). Diagnostic assessments and clinical symptom ratings were performed by experienced 
research clinicians. Initial and follow-up diagnoses were confirmed at diagnostic conferences 
attended by research faculty and staff, and chaired by an experienced psychiatrist. Blood 
samples were collected and clinical symptoms were evaluated prior to initiation of clinicians’ 
choice of antipsychotic agents. Follow-up blood samples were collected after 1 month, 6 
months and 12 months treatment by risperidone. Due to the funding limitations, there are some 
drop outs of base line subjects in those follow-up groups. The demographic table of subjects is 
shown below (Table 5). In addition, 52 age-, race-, BMI- and gender-matched HC subjects 
were also recruited for comparison.  
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Table 5. Demographic table in longitudinal study 
 a Male/Female. b Caucasian / African American / Pacific Asian / others.  
Abbreviations: HC, healthy control. Note: age and BMI data are expressed in means ± standard 
deviations; in HC group, one subject is missing sex and race information. Three subjects in 
baseline, 1 month (1M) and 6 months (6M) groups and one subject in 12 months (12M) group 
are missing BMI data due to missing height/weight values. 
3.2.2 Enzyme-linked immunosorbent assay 
The ELISA assay experimental design has been illustrated in section 2.2.3. We used same 
commercial ELISA kits as mentioned in section 2.2.3. In this chapter, adenosine, inosine and 
ADA levels were measured in chronic on-treatment and first-episode post-treatment groups. 
Data collected from chronic off-treatment, FEANS and control groups in Chapter 2 were used 
for comparisons and reference.  
 
  HC Baseline 1M 6M 12M 
Numbers  52 40 28 27 17 
Gender a 31/20 26/14 18/10 17/10 9/8 
Age  26.3 ± 7.4 22.7 ± 8.1 23.0 ± 8.0 23.2 ± 8.4 23.5 ± 8.5 
BMI 25.2 ± 4.4 23.3 ± 5.3 23.2 ± 6.0 23.2 ± 6.0 23.0 ± 6.4 
Race b 34/10/3/4 20/16/2/2 15/10/2/1 15/9/2/1 9/5/2/1 
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3.2.3 Data analysis 
1. General analysis procedures. Data analysis for this chapter followed the flow chart below 
(Figure 11). In brief, planned comparisons of analytes’ levels were made between on- and off-
treatment SZ groups via paired-t test. Correlations of adenosine and ADA were also analyzed 
in on- and off-treatment SZ groups via linear regressions. Fisher’s r to z transformation was 
applied and correlation coefficients of adenosine vs ADA among different groups were 
compared. On the other hand, comparisons of adenosine, inosine and ADA levels between 
short- and long-term treatment groups were made by mixed linear model analysis. All raw data 
and results were checked for distribution via quantile-quantile plots and main findings were 
summarized thereafter. All tests were two-tailed. 
 
2. Mixed linear model analysis procedures. Due to the differences of sample sizes and 
Figure 11. Data analysis flow chart for chapter 3.  
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covariates (Table 5) in the longitudinal study, mixed linear model might be a better option in 
this study. Here, three steps are shown below for mixed linear model analysis. 
1) Model structure selection. In linear mixed model, adenosine level was set as dependent 
variable and no covariate was included at this step. Look for the lowest schwarz's bayesian 
criterion (BIC) among covariance structures among variance components, toeplitz, auto-
regressive and unstructured models. BIC is a criterion for model selection among a finite 
set of models, and the model with the lowest BIC is preferred (Bhat and Kumar. 2010). 
2) Test if ADA can serve as the mediator in the conversion from adenosine to inosine.  
i. Test if covariates could affect adenosine levels. Set adenosine as the dependent 
variable. Set age, BMI, race, and sex as covariates. Test fixed effects for 
significance. 
ii. Test if adenosine levels can determine ADA’s level. Run this step for two times. 
For the first time, set ADA as dependent variable and find out which covariate (s) 
could potentially serve as cofounder. For the second time, only include adenosine 
and potential cofounder (s) identified in first time as covariates. Test fixed effect for 
significance.  
iii. Test if ADA’s level can determine inosine levels. Run this step for two times. For 
the first time, set inosine as dependent variable and find out which covariate (s) 
could potentially serve as cofounder. For the second time, only include ADA and 
potential cofounder (s) identified in first time as covariates. Test fixed effect for 
significance. 
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iv. Test if adenosine level can determine inosine levels directly. Run this step for two 
times. For the first time, set inosine as dependent variable and find out which 
covariate (s) could potentially serve as cofounder. For the second time, only include 
adenosine and potential cofounder (s) identified in first time as covariates. Test 
fixed effect for significance. 
v. Test if adenosine & ADA levels can determine inosine’s level. Run this step for two 
times. For the first time, set adenosine and ADA as dependent variables and find 
out which covariate (s) could potentially serve as cofounder. For the second time, 
only include adenosine, ADA and potential cofounder (s) identified in first time as 
covariates. Test fixed effect for significance. 
3) Test the difference of analytes’ levels among repeated measurements. Here we tested 
if adenosine, ADA and inosine levels were significantly changed among BL, 1M, 6M and 12M 
groups. Covariate (s) that showed significant (p < 0.05) levels in step 2) fixed effect tests were 
also included in this step as fixed effect covariates.  
i. Test if time would have effect on adenosine, ADA and inosine levels respectively. 
Each analyte level was set as dependent variable. Time intercept was set as 
random effect covariate and time was set as fixed effect covariate. Test fixed 
effect for significance. 
ii. Test if adenosine levels can predict inosine levels over time. Inosine levels was 
set as dependent variable. Time and adenosine were set as fixed effect covariates 
and time intercept was set as random effect. Test fixed effect for significance. 
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iii. Test if ADA levels can predict inosine levels over time. ADA levels was set as 
dependent variable. Time and ADA were set as fixed effect covariates and time 
intercept was set as random effect covariate. Test fixed effect for significance. 
iv. Test if adenosine levels can predict ADA levels over time. ADA levels was set as 
dependent variable. Time and adenosine were set as fixed effect covariates and 
time intercept was set as random effect covariate. Test fixed effect for 
significance. 
v. Test if adenosine & ADA levels can predict inosine levels over time. Inosine 
levels was set as dependent variable. Time, adenosine and ADA levels were set 
as fixed effect covariates and time intercept was set as random effect covariate. 
Test fixed effect for significance. 
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3.3 RESULTS 
3.3.1 Comparison of CSF analytes’ levels between on- and off-treatment SZ group 
As hypothesized, in CSF samples, significantly higher adenosine and ADA levels and 
significantly lower inosine levels were observed in on-treatment SZ group when comparing 
with those in off-treatment SZ group (Figure 12). Also, significantly lower adenosine levels in 
on-treatment SZ group were observed when comparing with those in HC group. Interestingly, 
no significant differences of ADA and inosine levels were found between on-treatment SZ 
group and HC group (Figure 12). 
 
 
 
 
 
 
 
 Figure 12. Comparisons of CSF adenosine, ADA and inosine levels among HC, on- and off-
treatment SZ groups.  
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3.3.2 Comparison of plasma analytes’ levels between on- and off-treatment SZ group 
In consistent with our finding in 3.3.1, in plasma samples, adenosine levels were observed that 
significantly higher in on-treatment SZ group than those in off-treatment SZ group. However, 
adenosine levels in on-treatment SZ group were observed that significantly lower than those in 
HC group. On the other hand, no significant changes of ADA and inosine levels were found 
between on-treatment SZ and off-treatment SZ groups (Figure 13). 
 
 
 
 
 
 
 
3.3.3 Correlations of adenosine and ADA in on- and off-treatment SZ group 
In general, we didn’t observe significant correlations between adenosine and ADA in either 
on-treatment SZ group or off-treatment SZ group. Correlations of adenosine with ADA in 
Figure 13. Comparisons of plasma adenosine, ADA activity and inosine levels among HC, 
on-treatment SZ and off-treatment SZ groups.  
Abbreviations: ADA = adenosine deaminase; HC = healthy control; OFF = off-treatment SZ 
group; ON = on-treatment SZ group. Units: adenosine and inosine are in µM, ADA is in I/U. 
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plasma showed a significant trend (p = 0.081) in on-treatment SZ group (Figure 14), but it 
should still be noted that this association is not significant (p > 0.05). Fisher’s z test did not 
show significant difference of correlation coefficients between on- and off-treatment groups in 
either CSF samples (z = -1.26, p = 0.2077) or plasma samples (z = -0.68, p = 0.4965). 
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Figure 14. Correlations of adenosine and ADA in on- and off-treatment SZ groups.  
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3.3.4 Mixed model analysis results in longitudinal study 
1. Model structure selection. In this step, adenosine levels was set as dependent variable and 
no covariate or factor is included. Look for the lowest BIC among variance components, 
toeplitz, auto-regressive and unstructured models. Based on results showed below (Table 6), 
variance components structure was selected as a variance-covariance matrix. 
Table 6. BIC values among different model structures 
 VC TP AR (1) UN 
BIC -128.0 -126.6 -126.6 -123.3 
Abbreviations: BIC = schwarz's bayesian criterion; VC = variance components; TP = toeplitz; 
AR (1) = auto-regressive; UN = unstructured. 
2.  Test ADA’s role as mediator in the conversion from adenosine to inosine. Five steps were 
then used to test ADA’s role in this study using variance components model structure. Model 
setups and results were summarized in table 7. Results showed that ADA activity levels can be 
predicted by adenosine levels. However, inosine levels cannot be predicted by adenosine or 
ADA or adenosine & ADA levels. Therefore, ADA cannot serve as the mediator in the 
conversion from adenosine to inosine here. With regard to other covariates, we found that age 
and race could also affect results (i.e. age and race are significant covariates in this test).  
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Table 7. Test ADA as mediator in the conversion from adenosine to inosine 
 a Covariate (s) that showed significant (p < 0.05) levels in fixed effect tests. b Includes age, 
BMI, sex and race. c Include covariates that have shown significant (p < 0.05) levels in the first 
run. Abbreviations: ADE = adenosine; ADA = adenosine deaminase; INO = inosine; NA = not 
applicable.  
3.3.5 Comparisons of analytes’ levels among FEANS baseline, post-treatment and 
HC groups. 
Here we used a mixed model approach to test if analytes’ levels were significantly changed by 
treatments over time. As was shown below (Table 8), adenosine levels was observed that 
significantly changed between BL and all post-treatment groups. Significantly higher 
adenosine levels were observed in 1M, 6M and 12M groups when comparing with BL group 
(Figure 15). However, no significant change of adenosine levels were found among 1M, 6M 
and 12M groups. As for ADA activity and inosine levels, no significant changes were found 
among baseline and all post-treatment groups. When compared with healthy control group, no 
significant changes were observed in any post-treatment time point groups with regard to 
adenosine, ADA activity or inosine levels (Figure 15). Also, adenosine levels can predict ADA 
Model 
First Run Second Run 
Dependent 
Variable 
Covariates Sig a 
Dependent 
Variable 
Covariates c Sig a 
1 
ADE ALL b Age NA NA NA 
2 
ADA ADE, ALL Race, ADE ADA Race, ADE Race, ADE 
3 
INO ADA, ALL  Race INO Race, ADA Race 
4 
INO ADE, ALL Race INO Race, ADE Race 
5 INO 
ADE, ADA, 
ALL 
Race INO 
ADE, ADA, 
ALL 
Race 
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levels over time by treatment while inosine cannot be predicted by adenosine, ADA or 
adenosine & ADA (Table 8). Within subjects, trajectories showed that over 90% of subjects 
have significantly higher adenosine levels in the 1M point when comparing with those in BL 
point. No significant trend of trajectories were observed from 1M point to 12M point. Also, no 
significant trend of trajectories were observed from BL to 12M point in terms of ADA activity 
and inosine levels (Figure 16). 
 
 Table 8. Mixed model analysis procedures and results 
a Covariate (s) that showed significant (p < 0.05) levels in fixed effect tests; b repeated measures 
from baseline to 12 months after the treatment. Abbreviations: ADE = adenosine; ADA = 
adenosine deaminase; INO = inosine. 
 
 
 
 
Model 
Dependent 
Variable 
Fixed effect covariates 
Random effect 
covariate 
Sig a 
1 ADE Time 
b, Age, Race Time intercept Time 
2 ADA Time, Age, Race Time intercept None 
3 INO Time, Age, Race Time intercept None 
4 INO Time, Age, Race, ADE Time intercept None 
5 INO Time, Age, Race, ADA Time intercept None 
6 ADA Time, Age, Race, ADE Time intercept ADE 
7 INO Time, Age, Race, ADE, ADA Time intercept None 
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Abbreviations: ADA = adenosine deaminase; HC = healthy control; BL = baseline; 1M = 1 month 
after baseline; 6M = 6 months after baseline; 12M = 12 months after baseline. Units: adenosine 
and inosine levels are in µM, ADA levels are in I/U. 
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Figure 15. Comparisons of plasma adenosine, ADA activity and inosine levels in HC, 
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Figure 16. Trajectory chart of (a) adenosine, (b) ADA activity and (c) inosine levels in the 
longitudinal study. 
b 
c 
Each line represents for the trajectory of each subject from baseline to 12 months after treatment. 
Some lines are not contiguous due to missing values of those analyte levels in follow-up groups. 
Detailed demographic information of this study group can be found in table 4.  
Abbreviations: ADA = adenosine deaminase; HC = healthy control; BL = baseline; 1M = 1 month 
after baseline; 6M = 6 months after baseline; 12M = 12 months after baseline. Units: adenosine 
and inosine levels are in µM, ADA levels are in I/U. 
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3.3.6 Correlations between adenosine and ADA in BL and post-treatment groups 
We then compared correlations between adenosine and ADA among BL and post-treatment 
groups. We didn’t find significant correlations between adenosine and ADA in BL or any post-
treatment groups. However, after long-term treatment (12M), the correlation became more 
significant when compared with short-term treatment (Figure 16). 
 
Figure 17. Correlations between adenosine and ADA in baseline and post-treatment 
groups.  
Abbreviations: ADA = adenosine deaminase. Units: adenosine and inosine levels are in µM, 
ADA levels are in I/U. 
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3.4 DISCUSSION 
Although accumulating evidence have suggested that ARs (especially A2AR) agonists could be 
the potential new generation of antipsychotics (Rimondini et al. 1997, Dixon et al. 1999, 
Bridges et al. 1987), D2R blocker remains the front-line antipsychotics in treating SZ patients 
at present time. Both first- and second-generation antipsychotics showed a high binding affinity 
of the D2R in striatum. As mentioned in the instruction section, activation of ARs would have 
inhibitory effect on D2R which is similar to the D2R blocker’s effect. In fact, when previous 
study looked into behavioral assays to predict antipsychotic activity, AR agonists block 
behaviors in a similar manner to dopamine receptor antagonists in animal model (Kafka and 
Corbett. 1996). Vice versa, clinical study showed that in SZ postmortem striatum, AR density 
was positively correlated with the dose of antipsychotics when those SZ patients were treated 
with chlorpromazine (D2R blocker) equivalents, implying an up-regulation of adenosine 
signaling by D2R blockers (Deckert et al. 2003). Based on robust pharmacological data 
foundations that supporting antipsychotics’ effect on adenosine signaling via D2R-AR 
interactions (Ferré. 1997, Ferré et al. 1994, Akhondzadeh et al. 2000), we hypothesized that 
antipsychotics can affect and restore analytes’ levels that related to adenosine signaling in SZ 
patients. Results in this chapter partially supported our hypothesis. 
Findings in 3.3.1 showed that antipsychotics can affect adenosine signaling in CNS. No 
significant difference was found between on-treatment SZ group and HC group in terms of 
inosine and ADA activity levels, which indicated that antipsychotics can normalize inosine and 
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ADA activity levels. These findings support the hypothesis that antipsychotics can at least 
partially restore back the adenosine signaling in the CNS. Combined with findings in chapter 
2, CSF inosine and ADA activity levels may serve as potential therapeutic indicators. While 
treatment can also significantly restore adenosine levels in on-treatment SZ group, significantly 
lower adenosine levels in off-treatment group were still found when compared to those in HC 
group. This observation suggested that those alterations of analyte levels along with the 
adenosine signaling deficits which were implied by observations in the SZ patients might be 
both trait and state features of SZ. Furthermore, such differences might reflect the limitation of 
current therapy which was based on the classical dopamine theory, and further contribute to 
negative & cognitive symptoms that are poorly responsive to current antipsychotics. In other 
words, D2R blocker cannot fully restore back the adenosine signaling in the CNS, and that 
might explain D2R blocker’s weakness in treating negative & cognitive symptoms.  
      Significantly higher adenosine levels in on-treatment SZ patient plasma indicated that 
treatment may also affect peripheral tissues. Similar to our findings in CSF, we observed 
significantly lower plasma adenosine levels in on-treatment SZ group than those in HC group, 
which also indicated that treatment cannot fully restore adenosine levels in peripheral tissues. 
However, plasma ADA activity and inosine levels were not significantly changed by treatment 
as situations in CSF. It looks like treatment has little impact in peripheral tissues, but if took 
findings in second chapter into consideration, findings with regard to analytes’ levels that were 
observed that were not significantly changed by antipsychotics may be reasonable. When 
comparing ADA activity and inosine levels in plasma between FEANS group and HC group 
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in 2.3.5, we also did not find significant differences. Therefore, we speculate that adenosine 
signaling in SZ is less altered in peripheral tissues than that in the CNS, and antipsychotics thus 
have less normalizing effect in peripheral tissues. More studies are needed to test differences 
of between peripheral tissues and CNS in terms of inosine & ADA activity levels. 
      As for the correlation between adenosine and ADA, results in 3.3.3 showed that 
correlations between adenosine and ADA could be partially restored by treatment, but based 
on our findings, this normalizing effect was only limited to peripheral tissues. The unchanged 
correlation between adenosine and ADA in the CSF after the treatment suggested that current 
treatment cannot normalize the disrupted connections within adenosine signaling in the CNS.   
After validation of the treatment effect on adenosine signaling, we then tested if short-
term treatment effects differ from the long-term ones in longitudinal study. Due to the 
differences of sample sizes and covariates among BL and post-treatment groups, we used 
mixed linear model in this study. Findings in Table 7 showed that age and race were significant 
covariates in fixed effect test, although relationships between adenosine and ADA was still 
significant while including age and race into the model. Based on published literature, no 
evidence has been suggesting race-related difference on adenosine signaling in human. With 
regard to age, one in vitro study suggested that responsiveness of the beta-adrenergic system 
in human vascular smooth muscle (Ford et al. 1992) was associated with age. Another animal 
study reported that the reduction of AR expression in rat heart (Jenner et al. 2004) might also 
be age-associated. But overall we did not find robust data directly support that age can 
significantly affect adenosine signaling.  
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With regard to analytes’ levels among BL and post-treatment groups in first-episode SZ 
patients, first, we found similar changing pattern of analytes’ levels by antipsychotics in this 
study (risperidone, second generation antipsychotics) in comparison of on-/off-treatment 
chronic SZ group (haloperidol, first generation antipsychotic). It validated previous 
pharmacological findings that antipsychotics affect adenosine signaling through AR-D2R 
interactions instead of AR-serotonin receptor interactions. As for comparisons made between 
post-treatment analytes’ levels and baseline analytes’ levels, findings here divergently 
validated the result in 3.3.2, suggesting that antipsychotics can significantly elevate plasma 
adenosine levels while having little impact on ADA activity and inosine levels. Within-subjects 
trajectory charts also supported this finding by showing significantly higher levels of adenosine 
in over 90% of subjects after the treatment in comparison with those in BL. Furthermore, no 
significant difference was observed between short- and long-term treatment effects with regard 
to adenosine, inosine and ADA activity levels. It indicated that when patients are on stable 
doses, adenosine, ADA activity and inosine levels are also in stable conditions. Trajectory 
analysis also supported this finding by showing no significant change over time among all post-
treatment groups. As for post-treatment analytes’ levels vs HC levels, however, it is important 
to note that adenosine levels in post-treatment groups was no longer significantly different with 
those in HC group. This finding is not consistent with findings in 3.2.1 and 3.2.2 when we were 
comparing on-treatment chronic SZ group and HC group. It may indicate that antipsychotics 
have the potential to fully restore adenosine levels at the early stage of the disease, but such 
capacity is lost as disease progresses to chronic stage.  
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     At last, we checked connections among adenosine, inosine and ADA in BL and post-
treatment groups. The hypothesis that ADA is the mediator of the conversion from adenosine 
to inosine was rejected by fixed effect tests. Also, inosine levels cannot be predicted by ADA 
or adenosine or ADA & adenosine levels in any of SZ groups. No significant correlation 
between adenosine and ADA was observed in BL any of the post-treatment groups. These 
findings suggested that adenosine signaling might not be the only part that was disrupted by 
SZ in purine pathway. Inosine and following enzymatic reactions may also get altered in SZ so 
that adenosine and ADA activity levels cannot predict inosine levels. Furthermore, these 
disrupted connections cannot be significantly improved by antipsychotics in the short-term. 
However, it tends to show a more significant correlation between adenosine and ADA in long-
term treatment (12M) group, which is similar with results in figure 14 (chronic on-treatment 
SZ group). These correlations were in inversed pattern which were same as the one in HC 
group. Mixed model analysis also showed that ADA activity levels could be predicted by 
adenosine levels during the treatment over time. These findings implied that treatment can 
gradually improve part of the connection between adenosine and ADA over time.  
3.5 CONCLUSION 
1. Results in this chapter indicated that antipsychotics can affect adenosine signaling in SZ 
patients. Results supported the hypothesis that treatment can at least partially restore adenosine, 
inosine and ADA activity levels in the CSF. Interestingly, plasma adenosine levels in first-
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episode SZ group is not significantly different with levels in HC group after the treatment, 
while in chronic SZ on-treatment group it is still significantly lower than those in HC group. 
More studies are needed to check if antipsychotics could better restore adenosine levels at the 
early stage of the disease than that in the chronic stage. 
2.  We found significant changes of ADA activity and inosine levels in on-treatment SZ group 
when compared to off-treatment group in the CSF. However, we did not see significant changes 
of these anlytes’ levels in the plasma either between on- and off-treatment groups or between 
baseline and post-treatment groups. It suggested that antipsychotics affect adenosine signaling 
more in the CNS than in peripheral tissues.  
3.  Findings indicated that antipsychotics can normalize inosine and ADA activity levels 
which were altered by SZ (results shown in 2.3.2) in the CNS. Therefore, CSF inosine and 
ADA activity levels may serve as potential therapeutic indicators.  
4.  Correlation analysis implied that treatment can gradually improve part of the connection 
between adenosine and ADA over time. Nevertheless, we didn’t see any of the post-treatment 
group showed significant correlation between adenosine and ADA. Also, adenosine levels in 
the CSF were observed that have significantly increased but still cannot be fully restored by 
the antipsychotics. These observations suggested that those changes of analyte levels in the SZ 
might be both trait and state features. Also, these results implied that current antipsychotics 
cannot fully normalize the disrupted adenosine signaling, which may contribute to current 
antipsychotic’s weakness in treating negative & cognitive symptoms among SZ patients.  
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Overall, findings in this chapter supported the central hypothesis that antipsychotics 
can affect and partially restore the adenosine signaling in SZ patients. Combined with findings 
in Chapter 2, adenosine signaling deficits which were suggested by data here are more likely 
to be trait and state features of SZ simultaneously. Also, results suggested that adenosine 
signaling modulator might be the silver lining in the endeavors of new antipsychotics R&D. 
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4.0  HOMEOSTATIC IMBALANCE OF PURINE PATHWAY IN SCHIZOPHRENIA 
4.1 BACKGROUND 
In human cells, purines are synthesized de novo from amino acids, formate and carbon dioxide 
as nitrogen and carbon donors. Adenosine signaling also serves as a signaling mechanism that 
is associated with the purine pathway. After being synthesized, adenosine is then metabolized 
to inosine, hypoxanthine, xanthine and ends in uric acid. In human, uric acid is the final product 
of purine catabolism (Linden and Rosin. 2006) and serves as a potent antioxidant and accounts 
for up to 65% of the total antioxidant capacity in the body (Wayner et al. 1987, Miller et al. 
1993). We previously reported a significant decrease of plasma uric acid levels in SZ patients 
(Yao et al. 1998), which linked the potential purine pathway homeostatic alterations to the 
oxidative stress. 
 It has long been proposed that at least in part, the neuropathological changes in SZ may 
result from oxidative stress mechanisms (Yao et al. 2001, Do et al. 2009, Fendri et al. 2006, 
Boskovic et al. 2011 and Flatow et al. 2013) while the precise components of such 
neuropathological alterations remain unclear. Under normal physiological conditions, free 
radical-mediated damage is opposed by the antioxidant defense system (AODS), which 
consisted a series of enzymatic and non-enzymatic components. These components act 
cooperatively at different sites in the free radical pathways. Under disease state, the AODS is 
compromised (Virit et al. 2009, Yao et al. 2006, Ranjekar et al. 2003) due to increased reactive 
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oxygen species (ROS) levels (Brieger et al. 2012, Koga et al. 2016). Consequently, unchecked 
ROS then triggers series of pathological processes such as DNA damage, lipid peroxidation 
and metabolic defects. In this dissertation, the metabolic defect we are interested in is the purine 
metabolism. 
In chapter 2 and chapter 3, we have observed adenosine signaling deficits in SZ patients 
which could be affected by antipsychotic therapy. In this chapter, we would like to explore the 
possible cause of such deficits. Adenosine theory states that it is the dysfunction of purinergic 
system that leads to the adenosine signaling deficits (Lara et al. 2006). Based on previous 
findings, we hypothesize that in SZ, an increased oxidative stress would cause the breakdown 
of AODS. As an important component of AODS, uric acid levels are consequently reduced. 
The reduction of the end product of purine pathway (uric acid) would lead to the metabolic 
shift of purine metabolism and eventually result in adenosine signaling deficits.  
To support this hypothesis, we tested three sub-aims in this chapter. Results & 
discussion are based on the flow of following sub-aims. This chapter also serves as a part of 
the aim 3 in dissertation.  
Aim 3.1.a. Test if homeostatic imbalance of purine pathway presents in SZ 
patients. We measured six major metabolites (guanosine, guanine, xanthine, xanthosine, 
hypoxanthine and uric acid) in the purine pathway other than adenosine, ADA and inosine. 
Comparisons of analytes’ levels were made between FEANS group and HC group. Then we 
compared ratios of product to precursor and detected the possible shift of the pathway in 
FEANS group in comparison to HC group.  
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Aim 3.1.b. Test if uric acid’s level reduction leads to adenosine signaling deficits 
in SZ. Here we checked the correlations between adenosine signaling and the end product (uric 
acid) of purine pathway in both FEANS and HC groups. 
Aim 3.1.c. Test if oxidative stress plays a role in causing uric acid’s level reduction. 
Here we measured levels of nitric oxide (NO) and malondialdehyde (MDA) in order to reflect 
oxidative stress levels. NO generates from L-arginine by nitric oxide synthase. After reacting 
with superoxide radicals, it then form peroxynitrite and contribute to oxidative stress level. NO 
is therefore been regarded as the marker of oxidative stress (Pierini and Bryan, 2015). MDA is 
the byproduct of lipid peroxidation and is generally used as the marker of lipid peroxidation 
(Gaweł et al. 2004, Del Rio et al. 2005). Besides uric acid levels, we also measured total 
antioxidant status (TAS) to reflect the total antioxidant capacity of the plasma in SZ patients 
and controls. First, we compared levels of these markers between FEANS group and HC group. 
Second, we tested the correlations between these markers and uric acid. 
4.2 EXPERIMENTAL PROCEDURES 
4.2.1 Clinical design 
Forty-two SZ patients were recruited from clinical services of the VA Pittsburgh Healthcare 
System (VAPHS). All procedures were approved by the VAPHS Highland Drive Institutional 
Review Board. After providing informed consent for their participation, patients were recruited 
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after having had at least two years of treatment on antipsychotics. Diagnostic assessments and 
clinical symptom ratings were performed by experienced research clinicians. Blood samples 
were collected and clinical symptoms were evaluated prior to initiation of clinicians’ choice of 
antipsychotic agents. Blood cotinine levels were measured and those patients who had levels 
over 10ng/mL were considered to be smokers. In addition, 53 age-, race-, BMI-, smoking habit- 
and gender-matched HC subjects were also recruited for comparison. The demographic table 
of subjects is shown below (Table 9).  
 
Table 9. Demographic table of recruited subjects 
a Male/Female. b Caucasian / African American / Pacific Asian / others. c Smoker/non-smoker 
Abbreviations: HC, healthy controls; FEANS, first episode antipsychotic naïve schizophrenia 
patients; BMI, body mass index. Note: age and BMI data are expressed in mean ± standard 
deviation; in HC group, one subject is missing gender and race information. Three subjects in 
FEANS group and one in DC group are missing BMI data due to missing height/weight values. 
  HC FEANS 
Numbers  53 42 
Gender a 32/20 26/14 
Age  26.0 ± 7.4 22.8 ± 8.0 
BMI 25.1 ± 4.4 23.4 ± 5.2 
Race b 34/11/3/4 22/16/2/2 
Smoking c  32/21 26/16 
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4.2.2 High-pressure liquid chromatography assay 
Guanoine, guanine, xanthine, hypoxanthine, xanthosine and uric acid were measured through 
high-pressure liquid chromatography coupled with electrochemical coulometric array system 
(HPLC-CMEAS). After centrifugation at 3000 rpm for 20min, 120 µL plasma samples 
including the internal standard (3, 4-Dihydroxybenzylamine) at 500ng/mL were injected into 
the HPLC system. Each sample was tested in duplicates and QCs were used to check the 
differences among different batches. Detailed methodology had been described earlier (Kristal 
et al. 2007, Shi et al. 2002). Briefly, the liquid chromatographic method employs an A mobile 
phase (10.3 g/ L sodium pentane sulfonate, 5 ml/L glacial acetic acid) and a B mobile phase 
(methanol/acetonitrile/isopropanol 8/1/1, 8 g/L lithium acetate, 20 ml/L glacial acetic acid). A 
gradient is run from 100% A to 100% B over 65 min. The electrochemical array of 12 series 
coulometric detectors is set from 0 to 900 mv in equal 60 mv increments from detector 1 to 12. 
In this mode, the compound passing through a coulometric electrode is oxidized by 100% of 
the thermodynamically possible amount. Results were in a characteristic signature for a 
compound expressed as a ratio on sequential electrodes. All chromatograms in this study were 
background-corrected to eliminate the base line drift inherent in gradient profiles. All responses 
matching the retention and electrochemical signature of compounds in the reference standard 
were exported in concentration units of ng/ml. Linear standard curve range of this assay is from 
2.5 ng/mL to 100 µg/mL. The Lower Limit of Quantification is 1.0 ng/mL. Intra assay 
percentage of CV is below 1.5% and inter assay percentage of CV is below 2.0%.  
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4.2.3 Enzyme-linked immunosorbent assay 
MDA was measured through ELISA kit from Abcam (ab118970). Linear standard curve range 
is from 1.33 µM to 20.67µM. The Lower Limit of Quantification is 0.05 µM. Intra assay 
percentage of CV is below 3.0% and inter assay percentage of CV is below 4.5%. TAS was 
measured through ELISA kit from Cayman (709001). Linear standard curve range is from 10 
µM to 100 mM. The Lower Limit of Quantification is 1 µM. Intra assay percentage of CV is 
below 5.0% and inter assay percentage of CV is below 8.0%. NO was measured through ELISA 
kit from Abcam (ab65328). Linear standard curve range is from 0.45 µM to 90 µM. The Lower 
Limit of Quantification is 0.33 µM. Intra assay percentage of CV is below 5.0% and inter assay 
percentage of CV is below 6.0%. Reading was obtained from PerkinElmer micro plate reader 
(Wallac 1420). MDA data was read at 530 nm, TAS data was read at 410 nm, and NO data was 
read at 540 nm. Each sample was tested in duplicates and QCs were used to check the 
differences between plates. 
4.2.4 Data analysis 
Comparisons of analytes’ levels were made between FEANS and HC groups via sample t test. 
Correlations of analytes were also analyzed in both FEANS and HC groups via linear 
regressions. All raw data and results were checked for distribution via quantile-quantile plots 
and main findings were summarized thereafter. All tests were two-tailed. 
 
 66 
4.3 RESULTS 
4.3.1 Comparisons of major metabolites’ levels in purine pathway between FEANS 
group and HC group 
As shown in Table 10, comparisons of purine pathway metabolites were made between FEANS 
group and HC group. Significant decrease of adenosine, hypoxanthine, guanine and uric acid 
levels were observed in FEANS group in comparison of HC group. No significant difference 
was found in inosine, xanthine, xanthosine and guanosine levels between FEANS group and 
HC group. 
Table 10. Comparisons of purine metabolites’ levels between FEANS and HC groups 
Abbreviations: HC = healthy controls; FEANS = first-episode antipsychotic naïve 
schizophrenia patients; STDEV = standard deviation. Means and standard deviations of uric 
acid are in µg/mL. All other levels of metabolite means and standard deviations are in ng/mL. 
Critical p value after Bonferroni correction: 0.0063. 
Metabolite 
HC FEANS 
p value 
Mean STDEV Mean STDEV 
Adenosine 130 24 88 18 0.0003 
Inosine 308 55 341 62 0.052 
Hypoxanthine 1785 310 1071 211 <0.0001 
Xanthine 151 39 180 44 0.011 
Xanthosine 19 4.7 21 5.0 0.566 
Guanine 7.2 1.7 4.6 1.4 <0.0001 
Guanosine 29 7.4 27 7.0 0.856 
Uric acid 50.1 9.3 35.1 7.9 <0.0001 
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4.3.2 Ratios of product to precursor in purine pathway between FEANS group and 
HC group 
As shown in table 11, ratios of product to precursor were calculated and comparison of these 
ratios were made between FEANS group and HC group. In most cases, product/precursor ratios 
are higher in FEANS group than those in HC group except UA/Xant, Xant/Gr and G/Gr, 
showing a general trend of pathway shift from precursors to products in SZ. 
Table 11. Comparisons of product to precursor ratios between FEANS and HC groups 
Abbreviations: HC = healthy controls; FEANS = first-episode antipsychotic naïve 
schizophrenia patients; STDEV = standard deviation; Ade = adenosine; Ino = inosine; Gr = 
guanosine; G = guanine; Xan = xanthine; UA = uric acid; Xant = xanthosine; Hx = 
hypoxanthine. Critical p value after Bonferroni correction: 0.0063. 
Product/Precursor 
HC FEANS 
p value 
Mean STDEV Mean STDEV 
Ino/Ade 2.7 1.3 4.3 1.8 <0.0001 
Xan/Hx 0.09 0.04 0.18 0.06 <0.0001 
Xan/Ade 1.4 0.8 2.3 1.1 <0.0001 
G/Gr 0.26 0.13 0.17 0.09 0.003 
Xan/G 30 21 64 43 <0.0001 
UA/G 10.5 9.7 13.0 10.5 0.022 
UA/Xant 2878 1176 1823 762 0.001 
Xant/Gr 0.77 0.47 1.07 0.81 0.038 
Xan/Xant 8.7 4.1 9.5 4.9 0.29 
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4.3.3 Homeostatic imbalance of the purine pathway in SZ 
We then graphed the metabolic map in order to reflect purine metabolic alterations in SZ. As 
shown in figure 17, a metabolic shift from adenosine and guanosine to xanthine was observed.  
 
 
 
 
 
4.3.4 Correlations between levels of analytes in adenosine signaling and levels of uric 
acid in HC and FEANS groups 
To test if adenosine signaling correlated with the end product of purine pathway, we checked 
correlations between adenosine signaling analytes and uric acid in HC and FEANS groups. 
Significant trend of correlation was found between uric acid and adenosine in HC groups while 
significant correlation was found between uric acid and adenosine in FEANS groups. 
Figure 18. Altered purine metabolism in FEANS group.  
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Purple arrows show the changes of metabolites’ levels and red arrows show the metabolic shift 
directions. Abbreviations: NP = nucleoside phosphorylase; DA = deaminase; XO = xanthine 
oxidase; XMP = xanthosine monophosphate. 
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Significant inverse correlations was found between uric acid and ADA in both HC and FEANS 
groups (Figure 18). 
 
  
 
 
Figure 19. Correlations between uric acid and (a) adenosine, (b) ADA and (c) inosine in 
HC and FEANS groups. 
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4.3.5 Comparisons of levels of oxidative stress markers and total antioxidant status 
between HC and FEANS groups 
Here we tested if levels of the oxidative stress marker (NO) and the lipid peroxidation marker 
(MDA) were different in FEANS group in comparison with those in HC group. We also 
compared TAS levels between these two groups to test if AODS were altered in SZ. As shown 
in Figure 19, significantly lower levels of TAS was found in FEANS group in comparison with 
those in HC group. Significantly higher levels of NO and MDA were found in FEANS group 
in comparison with those in HC group. 
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Figure 20. Comparisons of (a) TAS, (b) NO and (c) MDA levels between HC and FEANS 
groups. 
Abbreviations: HC = healthy controls; FEANS = first-episode antipsychotic naïve SZ patients; 
ADA = adenosine deaminase. Critical p value after Bonferroni correction: 0.0083 (significant), 
0.0167 (trend). Units: ADA is in I/U; Adenosine, uric acid and inosine are in ng/mL. 
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4.3.6 Correlations between oxidative stress markers and uric acid in HC and FEANS 
groups 
At last, we tested whether these indices that mentioned above are correlated with uric acid in 
HC and FEANS groups (Figure 20). Significant correlations were observed between uric acid 
and AODS in both HC and FEANS groups. Also, significant inverse correlations were found 
between uric acid and MDA in both HC and FEANS groups. On the other hand, we didn’t find 
any significant correlations between uric acid and NO in either HC or FEANS group. 
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4.4 DISCUSSION 
In this chapter, three specific questions were tested and answered here. First of all, we tested if 
the alterations of purinergic signaling present in SZ. Second, we tested if such alterations can 
be linked to adenosine signaling deficits. Third, we tested if oxidative stress plays a role in 
causing purinergic signaling alterations.  
Among eight purine metabolites that were analyzed by HPLC, four of them (adenosine, 
hypoxanthine, guanine and uric acid) were observed that levels were significantly lower in 
FEANS group than those in HC group. The other four metabolites’ levels in FEANS group 
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ADA = adenosine deaminase. Critical p value after Bonferroni correction: 0.0083. Units: uric 
acid is in ng/mL; AODS is in mM; NO and MDA are in µM. 
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Figure 21. Correlations between uric acid and (a) AODS, (b) NO and (c) MDA in HC and 
FEANS groups. 
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were not significantly different with those in HC group. No significantly increased levels of 
any metabolite were observed in FEANS group when comparing to HC group. These findings 
implied that there might be a hypofunction of purinergic signaling in the SZ, and adenosine 
deficits belongs to a part of it. This probably explained that we could not predict inosine levels 
solely by adenosine and ADA in previous chapters. However, by comparing ratios of product 
to precursor, we were able to estimate the possible shift of the metabolism in SZ. Specifically, 
we observed that the pathway shifts from adenosine and guanosine to the xanthine in FEANS 
group when comparing with the pathway in HC group. Xanthine could be metabolized by 
nucleoside phosphorylase to xanthosine (reversible) or by xanthine oxidase to uric acid. Since 
in FEANS group we have found a significant decrease of uric acid levels while xanthosine 
levels were not been significantly changed, we speculated that it is the decreased levels of uric 
acid that drives such metabolic shift.  
To further validate this assumption, we tested if uric acid levels can correlate with the 
adenosine signaling. Significant or significant trend of correlations between uric acid and 
adenosine implied that a reduced levels of uric acid associated with reduced levels of adenosine 
in purine metabolism. Significantly inversed correlation between uric acid and ADA suggested 
that a reduced levels of uric acid may lead to a higher activity levels of ADA, so that the 
metabolism could be shifted in favor of the uric acid production.  
We next looked for the possible reason that leads to the decreased levels of uric acid in 
SZ patients. Since numerous studies linked oxidative stress in SZ pathology (Yao et al. 2001, 
Do et al. 2009, Fendri et al. 2006, Boskovic et al. 2011 and Flatow et al. 2013) and uric acid 
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serves as an important component of AODS, we then tested the relationship between oxidative 
stress and uric acid. We chose MDA, NO and TAS as oxidative stress markers in this chapter 
based on previously established principles (Ho et al. 2013, Ghiselli et al. 2001). In consistent 
with previous findings (Das et al. 1995, Yao et al. 2004, Yao et al. 1998, Li et al. 2011, Zhang 
et al. 2007, Kuloglu et al. 2007), significantly higher levels of MDA & NO and significantly 
lower levels of TAS was found in FEANS group in comparison to HC group. With regard to 
correlations, significant correlations were observed between uric acid and AODS. Also, 
significant inverse correlations were found between uric acid and MDA. These findings 
suggested that uric acid may play an important role in the lipid peroxidation process and AODS. 
On the other hand, we didn’t find any significant correlations between uric acid and NO in 
either HC or FEANS group. This finding suggested that uric acid might not protect cells from 
ROS through the arginine-nitric oxide pathway. Future studies are required to reveal the 
underlying mechanism of uric acid’s protection against oxidative stress in the body. 
4.5 CONCLUSION 
1. Based on findings in this chapter, it is suggested that a hypofunction and homeostatic 
imbalance of purine pathway are associated with the SZ pathology. Interestingly, results 
suggested that adenosine, ADA and inosine are not the only parts of the purine pathway that 
has been altered by SZ. Since purine pathway has not been fully studied in the SZ pathology, 
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more data and evidence are needed to illustrate such metabolic defects and the potential clinical 
meanings behind it. 
2. Data suggested that purine pathway shifts from adenosine and guanosine to the xanthine. 
Results suggested that such shift may result from the compensatory response to the reduced 
uric acid levels in SZ patients. Significant correlations were noted between uric acid and 
analytes in the adenosine signaling, implied that adenosine signaling deficits may result from 
the metabolic shift of pathway which was initially caused by the decreased level of uric acid.  
3. Results suggested that oxidative stress may play an important role in causing the decreased 
level of uric acid. Increased levels’ oxidative stress markers and decreased TAS levels were 
observed in SZ, which supported the role of oxidative stress in SZ pathology. Significant 
correlations between uric acid and these markers suggested that oxidative stress may 
compromise AODS and reduce uric acid levels, and eventually triggers purine pathway 
metabolic defects. 
Based on findings in this chapter, we speculate that due to genetic or environmental 
factors, an increased oxidative stress level presents in SZ patients. The accumulation of 
oxidative stress in the body compromises the AODS and reduces uric acid levels in the body. 
The reduction of uric acid would lead to the compensatory response of the purine pathway and 
the metabolism would shift towards the direction in favor of uric acid production. As a 
consequence of metabolic shifts, adenosine signaling on the other end is then compromised 
and eventually developed into deficits. 
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5.0  ASSOCIATIONS OF ADENOSINE SIGNALING DEFICITS AND MEMBRANE 
LIPID DEFECTS IN SCHIZOPHRENIA 
5.1 BACKGROUND 
Lipid theory of SZ pathology states that an increased lipolysis of membrane phospholipids in 
the body system results in SZ symptoms. Specifically, previous findings (Gattaz et al. 1990, 
Pettegrew et al. 1991, Horrobin et al. 1991 and Noponen et al. 1993) indicated that in both CNS 
and peripheral tissues, an increased lipolysis of membrane phospholipids presents in SZ 
patients due to an increased PLA2 activity. Interestingly, adenosine’s role in mediating lipid 
metabolism especially on lipolysis via adenosine receptors has been highlighted by previous 
studies (Schwabe et al. 1974, Johansson et al. 2008). Details of the adenosine’s regulation on 
lipolysis are introduced in section 1.4. Under such context, we would like to test if adenosine 
signaling correlates to SZ pathology through the regulation of membrane lipid lipolysis. 
This chapter also serves as a part of the aim 3 in dissertation. We tested two sub-aims 
in this chapter. Results & discussion are based on the flow of following sub-aims.  
Aim 3.2.a. Test metabolic defects during the lipolysis of membrane phospholipids 
in FEANS group versus HC group. We are interested in studying membrane phospholipid 
lipolysis and resulting free fatty acids (FFAs) in SZ. As shown in figure 21, after the lipolysis 
from membrane phospholipids, FFAs serve as an active circulating pool in the body. They 
involve in many important biochemical reactions including regeneration of membrane 
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phospholipids, oxidation and production of prostaglandins (Zhou et al. 2017, Zhou et al. 2018). 
To test the lipid theory of SZ, we compared the total level of esterified fatty acids (FAs) in 
RBC samples and FFAs levels & profiles in plasma samples between FEANS and control 
groups. As an essential lipid constituent of cell membranes, membrane cholesterol levels in 
RBC samples among FEANS and control groups were also measured and compared between 
FEANS and HC group. In DC group, we did not measure esterified FAs and cholesterol levels. 
Aim 3.2.b. Test if adenosine correlates to lipid metabolic defects. We tested the 
correlations between adenosine and analytes (FAs, FFAs and cholesterol) that mentioned above. 
 
 
 
Figure 22. Lipolysis and FFAs’ functions in lipid metabolism. 
Abbreviations: PLA = phospholipase A2; ATP = Adenosine triphosphate. 
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5.2 EXPERIMENTAL PROCEDURES 
5.2.1 Clinical design 
FEANS and controls have been recruited from University of Pittsburgh western psychiatric 
institute site. Details of recruitment protocols have been fully illustrated in section 2.2.1. None 
of the subjects were on anticoagulants or lipid lowering agents before or during the study. 
5.2.2 Gas chromatography analysis 
Plasma FFAs and FAs bound on RBCs were quantitatively determined by capillary gas 
chromatography (GC) according to the procedure essentially the same as described by previous 
studies from Lepage (Lepage et al. 1988) and Ichihara (Ichihara et al. 1996), respectively. In 
brief, FFAs were extracted from 50 µl of plasma containing internal standard (Tridecanoic acid) 
and converted to methyl esters by acetyl chloride-methanol reagent. RBC FAs were extracted 
from 150µl of RBC samples containing internal standard (Diheptadecanoyl lecithin) and 
converted to methyl esters by methanolic KOH reagent. Then 1 µl of resulting fatty acid methyl 
esters was injected for GC analysis. Each sample was tested in duplicates and QCs were used 
to check the differences between batches. The procedure used for GC analysis has been 
described elsewhere (Reddy et al., 2004). Each sample was run under a splitless injection mode 
with helium as the carrier gas (3 mL/minute) and with an inlet pressure of 6.5 psi. Linear 
standard curve range of this assay is from 0.25 nmol/mL to 1250 nmol/mL. The Lower Limit 
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of Quantification is 0.05 nmol/mL. Intra assay percentage of CV is below 5.0% and inter assay 
percentage of CV is below 6.5%. Peaks on the chromatograms were identified by comparing 
the retention times with those of standard mixtures (Supelco) and were calculated by Agilent 
ChemStation. 
5.2.3 Cholesterol data collection 
RBC membrane cholesterol levels in subjects were collected through hospital clinical sheets. 
5.2.4 Data analysis 
The ANOVA test was used to test differences between FFAs levels among HC, DC and 
FEANS groups. Post-Hoc tests were corrected by Bonferroni corrections. Sample T-test was 
used to test differences between levels of esterified FAs and cholesterols in RBC samples. 
Pearson correlation coefficients were used to test the associations of analytes. Regression 
analysis was conducted and adjusted by Bonferroni corrections. All tests were two-tailed. 
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5.3 RESULTS 
5.3.1 Comparisons of total plasma FFAs, RBC cholesterol and esterified FAs levels 
between FEANS and HC groups 
As shown in figure 22, significantly lower membrane-bound FAs and FFAs levels were 
observed in FEANS group in comparison with those in HC group. No significance difference 
of membrane cholesterol levels was found between FEANS and HC groups.  
 
5.3.2 Comparisons of FFA profiles among FEANS, DC and HC groups 
We then compared the amount of plasma FFAs among FEANS, DC and HC groups. First, we 
observed a significantly decreased total levels of FFAs in FEANS group when comparing with 
a 
Abbreviations: HC = healthy controls; FEANS = first-episode antipsychotic naïve SZ patients. 
All units are in nmol/mL. *, p<0.0001. 
b c 
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Figure 23. Comparisons of (a) cholesterol, (b) bound fatty acids and (c) free fatty acids 
levels between HC and FEANS groups. 
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HC and DC groups. In consistent with the finding of decreased total FFAs levels in FEANS 
patients, we observed significant reduction of plasma FFAs mostly in saturated and n-6 fatty 
acid families (Table 12). Among saturated fatty acids, 16:0 is significantly decreased in FEANS 
group than in HC and DC groups. Among n-6 family fatty acids, 18:2n6c and 20:4n6 levels are 
significantly lower in FEANS group than in HC and DC groups.  
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Table 12. Table of fatty acid amounts among HC, DC and FEANS groups 
a All amounts are expressed as mean ± standard deviation. Units: nmol/mL. bp1: HC 
group vs DC group. p2: HC group vs FEANS group. p3: DC group vs FEANS group. 
Critical p value after Bonferroni correction: p=0.017. 
 
Fatty acid a HC  DC  FEANS   p1 b  p2 p3  
Saturates             
14:0 35 ± 16 29 ± 12 34 ± 20 ns ns ns 
15:0 4.5 ± 1.8 5.9 ± 1.6 3.9 ± 1.9 ns ns ns 
16:0 357 ± 95 356 ± 82 295 ± 74 ns 0.0007 0.007 
17:0 6.6 ± 4.5 6.6 ± 2.7 4.9 ± 1.8 ns ns ns 
18:0 109 ± 30 125 ± 28 98 ± 21 ns ns 0.0004 
21:0 5.1 ± 3.6 6.5 ± 2.5 4.5 ± 3.6 ns ns ns 
22:0 11.2 ± 4.7 12.6 ± 4.5 9.0 ± 3.2 ns ns ns 
Monoenes             
16:1n7t 5.8 ± 2.4 6.9 ± 2.3 4.5 ± 1.6 ns ns <0.0001 
16:1n7c 22.6 ± 10.7 26.7 ± 11.2 17.1 ± 7.8 ns ns 0.0003 
17:1 9.2 ± 7.0 12.2 ± 4.1 7.8 ± 5.3 ns ns 0.014 
18:1n9t 25 ± 14 27 ± 11 21 ± 12 ns ns ns 
18:1n9c 227 ± 73 213 ± 54 181 ± 46 ns 0.001 ns 
18:1n7 25 ± 10 28 ± 8 22 ± 8 ns ns ns 
Dienes             
18:2n6c 314 ± 75 322 ± 65 255 ± 62 ns <0.0001 <0.0001 
20:2n6 5.1 ± 3.6 5.1 ± 2.3 3.6 ± 2.4 ns 0.013 ns 
Trienes             
18:3n6 5.6 ± 2.7 5.3 ± 1.9 4.6 ± 2.1 ns ns ns 
20:3n6 5.3 ± 2.9 5.3 ± 2.3 4.3 ± 2.8 ns ns ns 
Tetraenes             
20:4n6.. 70 ± 17 75 ± 10 60 ± 16 ns 0.004 0.0004 
22:4n6.. 13.4 ± 4.6 15.4 ± 4.1 12.9 ± 4.5 ns ns ns 
Pentanenes             
22:5n3.. 5.0 ± 2.6 5.7 ± 2.2 3.9 ± 2.7 ns ns ns 
Hexananes             
22:6n3.. 26 ± 9 25 ± 7 22 ± 3 ns 0.004 ns 
Totals             
Saturates 529 ± 129 542 ± 118 450 ± 91 ns 0.001 0.002 
n-3  31 ± 10 31 ± 8 26 ± 5 ns 0.006 ns 
n-6  413 ± 90 428 ± 65 340 ± 74 ns <0.0001 <0.0001 
Totals 1288 ± 297 1315 ± 213 1069 ± 205 ns <0.0001 0.0003 
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Disrupted correlations within fatty acid families were also observed in FEANS group 
but not in HC or DC groups. While significant correlations were still observed in saturated fatty 
acid family (Figure 23) among all three groups, significant correlations between 17:0 and 17:1 
as well as 18:3n6 and 20:3n6 were found only in HC and DC subjects but not in FEANS 
subjects (Figure 24). 
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Figure 24. Comparisons of correlations between precursor and product fatty acids among 
HC, DC and FEANS groups 
Figure 25. Comparisons of correlations between precursor and product fatty acids among 
HC, DC and FEANS groups. 
5.3.3 Correlations between adenosine and FA levels in HC and FEANS groups 
In section 5.3.1, significantly decreased levels of membrane-bound FAs and plasma FFAs were 
observed in FEANS group when comparing with those in HC and DC groups. Here we tested 
Abbreviations: HC = healthy controls; FEANS = first-episode antipsychotic naïve SZ patients. 
All units are in nmol/mL. Critical p value after Bonferroni correction: 0.017.           
Abbreviations: HC = healthy controls; FEANS = first-episode antipsychotic naïve SZ patients. 
All units are in nmol/mL. Critical p value after Bonferroni correction: 0.017. 
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if such alterations correlate with adenosine levels. Results in figure 25 showed that in both HC 
and FEANS groups, adenosine levels significantly correlate with membrane-bound FAs but 
not with FFAs. 
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Abbreviations: HC = healthy controls; FEANS = first-episode antipsychotic naïve SZ patients. 
All units are in nmol/mL. Critical p value after Bonferroni correction: 0.017. 
Figure 26. Correlations between adenosine and (a) esterified FAs and (b) FFAs in HC 
and FEANS groups. 
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5.4 DISCUSSION 
In this chapter, we mainly compared RBC cholesterol, membrane-bound (esterified) FAs and 
plasma FFAs levels between HC and FEANS groups. We did not find any significant change 
of cholesterol levels in FEANS RBC samples when compared to levels in HC RBC samples. 
This finding indicated that cholesterol may not play a role in the membrane phospholipid 
alterations in SZ. Significantly decreased levels of membrane-bound FAs were found in 
FEANS group in comparison to HC group. It corroborated the lipid theory of SZ pathology by 
suggesting an increased lipolysis on RBC cell membranes in SZ patients. Increased lipolysis 
of cell membranes and underlying clinical significance in SZ had been well-documented 
(Gattaz et al. 1990, Pettegrew et al. 1991, Horrobin et al. 1991 and Noponen et al. 1993) in 
previous publications. 
The resulting FFAs after membrane lipids lipolysis, however, had been scarcely studied 
in the pathology of SZ. Since it could help us to understand the metabolism of membrane lipids 
after the lipolysis, we measured FFAs levels and calculated compositions of the FFAs profiles 
in FEANS group and compared them with those in control groups. Instead of observing 
increased FFAs from increased breakdown of membrane phospholipids, we found a significant 
lower levels of FFAs in FEANS patients than in control subjects. These findings may suggest 
three important implications with regard to SZ pathology. First, reduced total FFAs levels may 
imply an increased regeneration of cell membranes. Reduced levels of plasma FFAs may 
reflect a depleted pool of those fatty acids resulting from an increased demand of cell 
 87 
membrane regeneration during the early course of SZ development. Notably, while there is a 
general trend of decrease among all families of FFAs, we found that n-6 and saturated family 
FFAs levels in FEANS group are significantly lower than HC and DC groups. It may imply 
that these two FA families are the most vulnerable ones that been altered at the early stage of 
SZ. 
Second, our findings reflected the disturbance of FA biosynthesis and following beta-
oxidations at the early course of SZ. Most FFAs are synthesized by elongases & desaturases, 
and then go through beta-oxidation to generate energy (Figure 25). Although some of precursor 
to product correlations persist across disease and normal status, others appear to be lost in 
FEANS group. Results suggested that the potential for steady formation of fatty acids is altered 
early in the course of illness. While alterations were also observed in saturated fatty acid family, 
it is the n-6 fatty acid family that seems to be most altered in FEANS subjects. This finding 
suggested that n-6 fatty acid biosynthesis are more disrupted than other fatty acid families at 
the early course of the disease. Furthermore, previous studies also showed that several fatty 
acid beta-oxidation enzymes were significantly increased in SZ patient brain, which indicates 
an enhanced beta-oxidation in FEANS patients (Prabakaran et al. 2004). Yang et al (2017) also 
suggested an up-regulated beta-oxidation process in the SZ patient serum by comparing 
product to precursor ratios of FAs. Therefore, we hypothesize that the increased lipolysis of 
membrane lipids and the reduction of following plasma FFAs may due to the hyperactivity of 
beta-oxidation in SZ pathology. 
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Third, findings may help to explain the blunted niacin-induced skin flushing in a 
subgroup of SZ patients. Niacin test refers to the evaluation of aqueous methyl nicotinate’s 
effect on the production of prostaglandins and the following cutaneous capillary vasodilatation. 
The mechanism of the niacin response has been illustrated by previous literatures (Messamore 
and Yao, 2016). In normal condition, niacin induces flushing response mediated through niacin 
Abbreviation: FA = fatty acid; Δ = desaturase. Different families are indicated by different 
colors. 
Figure 27. Fatty acid metabolic pathways. 
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receptors, and activates PLA2 to release arachidonic acid (Tang et al. 2006). Released free 
arachidonic acid is the substrate of vasodilatory prostaglandins (PGD2 and PGF2) and these 
prostaglandins activates prostanoid receptors to dilate cutaneous blood vessel (Lai et al. 2007) 
and eventually lead to skin flush (Benyó et al. 2005, Maciejewski-Lenoir et al. 2006, Morrow 
et al. 1989, Morrow et al. 1992). It is interesting to note that blunted niacin-induced skin 
flushing was found in a subgroup of SZ patients. Previous literature pointed out that in aqueous 
methyl nicotinate test on skin, schizophrenics were highly significantly different from the 
controls among all concentrations of aqueous methyl nicotinate (Ward et al. 1998). Moreover, 
at certain concentration, 83% of schizophrenics but only 23% of controls were having a zero 
or minimal response to aqueous methyl nicotinate (Ward et al. 1998). This study was further 
replicated by Puri et al on 2001 and suggested that this test may be useful clinically in the 
diagnosis of SZ (Puri et al. 2001). While the cause of the blunted skin flushing in SZ is still 
unclear, our findings of significant decreased arachidonic acid (20:4n6) as well as its precursors 
in FEANS patients may offer a possible explanation for the underlying mechanism. Based on 
our findings, it is speculated that reduced levels of 18:2n6 and 20:4n6 may reflect a decreased 
pool for subsequent production of prostaglandin vasodilators, which leads to the blunted niacin-
induced flushing response in those SZ patients. 
In this chapter, we are interested in learning adenosine’s effect on membrane lipid 
lipolysis in SZ. According to previous findings, activation of A1R can inhibit lipolysis through 
enhancing insulin’s inhibitory effect on the activity of phospholipase (Schwabe et al. 1974, 
Johansson et al. 2008). The mechanism by which adenosine enhances insulin’s effect is 
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mediated by the activation of cAMP-dependent protein kinase (Koupenova et al. 2013). As 
expected, our results demonstrated a significant correlation between adenosine and membrane 
bounded total FA levels. Since in chapter 2, reduced adenosine levels were observed and 
adenosine signaling deficits were suggested in SZ patients, thus it is speculated that the 
increased membrane lipolysis and reduced levels of membrane FAs may result from a reduced 
adenosinergic activity in SZ. However, no significant correlation was observed between total 
FFAs levels and adenosine in either HC or FEANS group. This finding might be due to the 
multiple sources that producing FFAs in the plasma. Besides originated from membrane 
phospholipids, plasma FFAs can also be produced from the lipolysis of triglycerides and 
lipoproteins (Wang et al. 2009, Teusink et al. 2003). Also, since plasma FFAs served as a 
dynamic circulating pool of FAs, its total levels can also be affected by multiple downstream 
biochemical reactions such as beta-oxidation and prostaglandin biosynthesis. More research 
are needed to investigate plasma FFAs’ origins and its metabolisms in SZ. 
5.5 CONCLUSION 
1. In consistent with lipid theory of SZ, significantly reduced membrane-bound FAs’ levels 
were observed in SZ patients in comparison to HC subjects, implying an increased lipolysis of 
membrane phospholipids in SZ pathology. The analysis of plasma FFAs’ levels and lipid 
compositions also yield interesting results. Specifically, we observed a general trend of FFAs’ 
level reduction and biosynthesis disturbance in FEANS group. We also associated these 
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metabolic dysfuntions with clinical implications with regard to SZ pathology. 
2. We found significant correlation between adenosine and membrane FAs in both HC and 
FEANS groups, suggesting that adenosine level reductions might contribute to membrane 
phospholipid defects in SZ pathology. 
To summarize, based on all information gathered, a hypothesis was made that 
adenosine signaling deficits were at least partially contributed to membrane phospholipid 
defects in SZ. Specifically, since adenosine signaling was reduced in SZ, adenosine’s up-
regulating effect on insulin activity through cAMP-dependent protein kinase pathway was also 
diminished. As insulin activity was decreased, the inhibitory effect of insulin on membrane 
PLA2 activity through phosphoinositide 3-kinases pathway thus was weakened. Consequently, 
lipolysis activity through membrane PLA2 was increased and finally resulted in membrane 
phospholipids defects in SZ which has been illustrated in the lipid theory. However, more 
evidences with regard to adenosine’s role in lipolysis are still in need to validate this hypothesis. 
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6.0  ASSOCIATIONS OF ADENOSINE SIGNALING DEFICTIS AND DOPAMINE 
METABOLIC DEFECTS IN SCHIZOPHRENIA 
6.1 BACKGROUND 
Dopamine theory states that it is the increased dopaminergic signaling in striatal region that 
leads to SZ symptoms. Adenosine’s role in regulating dopaminergic signaling in the striatum 
and findings of dopamine metabolism alterations have been summarized in section 1.5. Thus 
we tested if those alterations of dopaminergic signaling can also be found in the FEANS group 
when comparing with HC group, and if so, whether such alterations could be linked to 
adenosine levels or not. 
This chapter also serves as a part of the aim 3 in the dissertation. We tested two sub-
aims in this chapter. Results & discussion are based on the flow of following sub-aims.  
Aim 3.3.a. Test if there is a hyperactivity of dopamine metabolism in the SZ patient 
plasma. As is shown in figure 27, dopamine is synthesized from phenylalanine (Phe) and is 
eventually metabolized to homovanillic acid (HVA). Because of the extremely low levels (less 
than 30 pg/mL) of dopamine, 3-methoxytyramine and 3, 4-dihydroxyphenylacetic acid in 
plasma, we measured levels of Phe, tyrosine (Tyr) and HVA to indirectly reflect dopamine 
metabolism in the peripheral tissues of SZ patients. Previous findings about Phe and Tyr plasma 
levels in SZ have been summarized in table 2. HVA is the final product of dopamine 
metabolism. Plasma HVA levels is often used to predict striatal dopaminergic activity (Pickar 
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et al. 1988, Beuger et al. 1996) and treatment outcomes (Mazure et al. 1991, Davila et al. 1988). 
Since dopamine theory suggested a hyperfunction of striatal dopamine metabolism in SZ 
patients, we are predicting higher levels of Phe, Tyr and HVA in the FEANS group than those 
in the HC group. 
Aim 3.3.b. Test if reduced adenosine levels link to the dopamine metabolic defects 
in SZ. In chapter 2, significantly decreased plasma adenosine levels were observed in the 
FEANS group when comparing with those in control groups. In this aim, we will test if 
adenosine levels correlate with analytes’ levels in the dopamine metabolism.  
 
6.2 EXPERIMENTAL PROCEDURES 
6.2.1 Clinical design 
Subjects were recruited through the protocol that has been illustrated in section 2.2.1. Samples 
were collected from forty FEANS patients and fifty-two age-, gender-, BMI- and race-matched 
Figure 28. Dopamine metabolic pathway. 
Abbreviations: PAH = phenylalanine hydroxylase; TH = tyrosine hydroxylase; DDC = dopa 
decarboxylase; COMT = catechol-O-methyltransferase; MAO = monoamine oxidase; 3-MT =  
3-methoxytyramine; DOPAC = 3, 4-dihydroxyphenylacetic acid; HVA = homovanillic acid. 
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HC subjects. Sample graphic table is the same as shown in table 3. Samples from DC group 
were not involved in this study. 
6.2.2 Gas chromatography analysis 
Phe and Tyr levels in plasma were quantitatively determined by GC. Samples were prepared 
according to the instruction of amino acid analysis kit from Phenomenex (AG0-7184). Briefly, 
50µL of internal standard (Norvaline at 200 µM) was added into each 100 µL plasma sample 
and samples were then transferred into solid-phase extraction tube. Organic derivatizing 
reagent (2,2-dihydroxyindane-1,3-dione) was then added into the tube. At last, amino acids 
were extracted in organic phase and 1 µL of each sample was injected into the GC system. 
Each sample was tested in duplicates and QCs were used to check the differences between 
batches. Each sample was run under a splitless injection mode with helium as the carrier gas 
(1.5 mL/minute) and with an inlet pressure of 6 psi. Peaks on the chromatograms were 
identified by comparing the retention times with those of standard mixtures (EZfaast) and were 
calculated by Agilent ChemStation. Linear standard curve range of this assay is from 5 µM to 
400 µM. The Lower Limit of Quantification is 0.1 µM. Intra assay percentage of CV is below 
5.0% and inter assay percentage of CV is below 5.5%. 
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6.2.3 High-pressure liquid chromatography assay 
HVA was determined by the HPLC-CEMAS. Protocol and procedures of the assay have been 
illustrated in section 4.2.2. Linear standard curve range of this assay is from 2.5 ng/mL to 100 
µg/mL. The Lower Limit of Quantification is 1.0 ng/mL. Intra assay percentage of CV is below 
1.5% and inter assay percentage of CV is below 2.0%. 
6.2.4 Data analysis 
Sample T-test was used to test differences of analytes’ levels between FEANS and HC groups. 
Pearson correlation coefficients were used to test the associations of analytes. Regression 
analysis was conducted and corrected with Bonferroni adjustment. All tests were two-tailed. 
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6.3 RESULTS 
6.3.1 Comparisons of plasma analytes’ levels in dopamine metabolism between 
FEANS and HC groups 
Phe and Tyr are important precursors in the biosynthesis of dopamine. Thus we first compared 
these two amino acids’ levels in the plasma between FEANS and HC groups. As expected, 
results showed significantly higher levels of Phe and Tyr in FEANS group than those in the 
HC group (Figure 28). We also compared levels of the end product of dopamine metabolism 
(i.e. homovanillic acid) in the plasma between FEANS and HC groups. Plasma HVA levels in 
the FEANS group were also observed that were significantly higher than those in the HC group 
(Figure 28). 
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Figure 29. Comparisons of (a) phenylalanine, (b) tyrosine and (c) homovanillic acid levels 
between HC and FEANS groups. 
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6.3.2 Correlations between adenosine and analytes in the dopamine metabolism in 
HC and FEANS groups 
We then tested correlations between adenosine and analytes in the dopamine metabolism. 
Interestingly, we didn’t observe significant correlation between adenosine and phenylalanine 
or between adenosine and tyrosine in either FEANS group or HC group (Figure 28). However, 
we found significant inverse correlations between adenosine and HVA in both groups (Figure 
28). 
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6.4 DISCUSSION 
In this chapter, we have determined plasma levels of Phe, Tyr and HVA in FEANS and HC 
groups. Significantly increased Phe, Tyr and HVA levels were observed in FEANS group when 
comparing with HC group. Data here supported those previous findings that reported a 
hyperfunction of dopaminergic activity in the peripheral tissues of SZ patients which linked to 
striatal dopamine hyperfunctions in SZ (Howes et al. 2009, Rao et al. 1992, Sumiyoshi et al. 
2000). Furthermore, our findings suggested that both the biosynthesis and the metabolism of 
dopamine have been increased at the early course of SZ. However, since we were not able to 
measure dopamine and its two direct metabolites (3-methoxytyramine and 3, 4-
Figure 30. Correlations between adenosine and (a) phenylalanine, (b) tyrosine and (c) 
homovanillic acid in HC group and FEANS group. 
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dihydroxyphenylacetic acid) in this dissertation, the mechanism of the increased biosynthesis 
of dopamine that leads to increased levels of the final product is still not clear. In other words, 
whether both of the dopamine direct turnovers’ levels have been altered by SZ remains 
unknown at current stage and this issue should be noted as a limitation of our present study. 
More research are required to investigate whether increased plasma levels of HVA were 
resulted from increased levels of both of the dopamine direct metabolites (3-methoxytyramine 
and 3, 4-dihydroxyphenylacetic acid) or from one of them.  
To test adenosine’s effect on dopamine metabolism, we correlated adenosine with 
metabolites in dopaminergic signaling in both FEANS and HC groups. No significant 
correlations between Phe and adenosine or between Tyr and adenosine were observed. This 
finding implied that adenosine may not have an impact on the biosynthesis of the dopamine. 
On the other hand, the significant inverse correlation between HVA and adenosine were 
observed, which suggested that adenosine may have an inhibitory effect on dopaminergic 
signaling after dopamine is synthesized. Previous findings from animal models also implied 
that adenosine mainly inhibit dopaminergic signaling through ARs-DRs interactions (Ferré et 
al. 1997, Ferré et al. 2008, Le Moine et al. 1997). According to results, we speculated that such 
inhibitory effect was not altered by SZ, as we found significant inverse correlations between 
adenosine and HVA in both FEANS and HC groups. Instead, it is possible that it is the 
decreased levels of adenosine that contributed to the abnormal dopaminergic signaling in SZ.  
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6.5 CONCLUSION 
1. Significantly increased dopaminergic signaling metabolites’ levels in FEANS group were 
observed when comparing to HC group, suggesting a hyperfunction of dopaminergic signaling 
in peripheral tissues at the early course of the SZ. 
2. Adenosine seems cannot affect the biosynthesis of dopamine. Instead, levels of the end 
product in dopamine metabolism (HVA) were observed that inversely correlate with adenosine 
levels, which supported adenosine theory in that adenosine could inhibit the dopaminergic 
signaling in peripheral tissues at least partially via ARs-DRs interactions. 
In conclusion, adenosine signaling deficits might play an important role in the hyperfunction 
of dopaminergic signaling that have been wee-documented in the SZ pathophysiology. 
Specifically, it is speculated that decreased adenosine levels may cause the decreased inhibitory 
effect of adenosine on dopaminergic signaling via ARs-DRs interactions. The hyperfunction 
of dopaminergic signaling then leads to the onset of clinical symptoms especially positive ones 
in the SZ symptomatology. 
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7.0  CLINICAL ASSIOCIATIONS OF ADENOSINE SIGNALING AND 
SCHIZOPHRENIA SYMPTOMATOLOGY 
7.1 BACKGROUND 
In the United States, SZ is diagnosed based on the criteria in the American Psychiatric 
Association's Diagnostic and Statistical Manual of Mental Disorders (DSM). First, to be 
diagnosed with SZ by DSM IV (Fourth Edition. 1994, 2007), two of the following 
characteristic symptoms need to be met over at least one month: delusions, hallucinations, 
disorganized speech, grossly disorganized or catatonic behavior or negative symptoms (e.g. 
flattened affect, alogia, amotivation, avolition). Second, the person should have social or 
occupational dysfunction or failure to achieve a level of functioning expected for their age and 
socioeconomic background. Third, continuous signs of the disturbance must persist for a 
minimum of six months. Fourth, schizoaffective disorder and mood disorders have been ruled 
out (American Psychiatric Association 2007). For studies relevant to this dissertation, detailed 
symptom assessments and diagnostic assessments were fully reviewed (Andreasen et al. 1992, 
Andreasen et al. 1995) using the principles of CASH (comprehensive assessment of symptoms 
and history). Rating data used in this dissertation also meets with such standards.  
The adenosine theory hypothesizes that adenosine signaling deficits will correlate with 
SZ symptoms. Specifically, it proposes that adenosine signaling deficits correlate positively 
with positive symptoms via DRs-ARs interactions and correlate positively with negative & 
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cognitive symptoms via NMDARs-ARs interactions (Lara et al. 2006, Boison et al. 2012). This 
assumption is based on two sources of supporting evidences. Firstly, as introduced in section 
1.2, adenosine is the up-stream regulator of dopaminergic signaling (S. Ferré et al. 1991a, S. 
Ferré et al. 1991b, Salmi et al. 2005) and glutamatergic signaling (Boison. 2008, Okamura et 
al. 2004) via ARs. Secondly, striatal dopaminergic signaling hyperfunction has been mostly 
linked to positive symptoms (Davis & Kahn. 1991, Howes & Kapur. 2009) while NMDAR 
hypofunction has been linked to cognitive & negative symptoms (Coyle & Tsai. 2004, Farber. 
2003) of SZ. However, since adenosine has been scarcely studied in psychiatry, few studies 
have directly correlated adenosine with SZ symptoms. In previous chapters, we have tested the 
presence of adenosine signaling deficits in SZ patients. We also found that adenosine signaling 
could be affected by antipsychotics and correlates to other metabolic defects in SZ. Here in this 
chapter, we will test whether adenosine signaling deficits correlate with SZ symptoms.  
This chapter also serves as aim 4 in the dissertation. We correlated positive, negative 
and global symptom assessment with adenosine signaling in FEANS and chronic off-treatment 
SZ groups. 
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7.2 METHODS 
7.2.1 Patients recruitment 
1. Chronic SZ group. The recruitment procedure has been introduced in 2.2.1. 
2. FEANS group. The recruitment procedure has been introduced in 2.2.1. 
7.2.2 Adenosine, ADA and inosine data collection. 
Biochemical data were collected using ELISA assay applied to clinical samples mentioned in 
2.2.1. Details of experimental procedure have been revealed in 2.2.2. 
7.2.3 Clinical evaluation 
Data were collected from hospital records. Clinical interviews were conducted on each subject 
by a mental health professional. Brief Psychiatric Rating Scale (BPRS), Scale for the 
Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms 
(SANS) and Global Assessment of Functioning Score (GAS) were used with the FEANS group 
evaluation (Overall and Gorham. 1962). SAPS and SANS were used with the chronic on-/off-
treatment SZ group. The BPRS contains 24 items that reflect a broad range of symptomatology, 
including mood symptoms (depressive and manic), and anxiety symptoms in addition to 
psychotic symptoms. For studies here, the positive (BPRS-P, including conceptual 
disorganization, suspiciousness, hallucinatory behavior and unusual thought content) and 
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negative (BPRS-N, including emotional withdrawal, motor retardation and blunted affect) 
symptom subscales (Ventura et al. 2000) were used. Each item focuses on one specific 
symptom (such as hallucinations, depressive mood, motor retardation, grandiosity, etc.). Each 
item ranges from 0 (no symptom) to 7 (most severe) to reflect the severity of each symptom. 
Total Scores were used for all correlation analyses. SAPS and SANS were also used to assess 
positive and negative symptoms, respectively. The SAPS has 34 items (including four global 
items) that constitute four subscales measuring hallucinations, delusions, bizarre behavior and 
positive formal thought disorder. The SANS has 25 items (including five global items) that 
constitutes five subscales measuring affective flattening or blunting, alogia, avolition-apathy, 
anhedonia-asociality and attention. Each item was also scored by clinicians from 0 (no 
symptom) to 5 (most severe) to evaluate the degree of each symptom. Total Scores were used 
for the correlation analysis. The GAS was used to rate how serious a mental illness may be. It 
measures severity of smptoms and how much a person's symptoms affect his or her daily life 
on a scale of 0 (profound negative effects on daily functioning) to 100 (no symptoms present 
and no deficits in daily functioning). Diagnoses were confirmed at diagnostic conferences 
attended by research faculty and staff, and chaired by an experienced psychiatrist. 
7.2.4 Data analysis 
Correlations between adenosine signaling and symptom assessment scales were tested in 
FEANS group and off-treatment SZ group via linear regressions. Bonferroni correction was 
applied in each of the regression. All tests were two-tailed. 
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7.3 RESULTS 
7.3.1 Correlations between adenosine signaling and SZ symptoms in FEANS group 
As hypothesized, Results showed significant correlations between adenosine signaling and 
positive symptoms. As shown in Figure 30, significantly inversed correlations were observed 
between adenosine and positive symptoms as measured on the BPRS and SAPS. Significant 
positive correlation was observed between ADA and BPRS positive symptoms. A significantly 
inversed correlation was observed between inosine and positive symptoms as measured on the 
SAPS. Also, significant correlations were found for adenosine and ADA with GAS scores. 
However, none of the negative symptom scales correlated with adenosine signaling (Figure 31).  
7.3.2 Correlations between adenosine signaling and SZ symptoms in chronic off-
treatment SZ group 
As hypothesized, in this group, we found significant inverse correlations between adenosine 
and SAPS in both plasma and CSF. No correlation was observed between SAPS scores and 
ADA or inosine (Figure 32). However, SANS scores did not correlate with any of the analytes 
in the adenosine signaling (Figure 33). 
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a 
b  
 
 
Abbreviations: BPRS-P = brief psychiatric rating scale-positive symptoms; SAPS = scale for the 
assessment of positive symptoms; GAS = global assessment of functioning score. Critical p value 
after Bonferroni correction: 0.0167. 
 
c 
Figure 31. Correlations between symptoms scales and (a) adenosine, (b) ADA and (c) 
inosine. 
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Figure 32. Correlations between symptoms scales and (a) adenosine, (b) ADA and (c) 
inosine. 
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Figure 33. Correlations between positive symptoms and (a) adenosine, (b) ADA and (c) 
inosine in CSF and plasma. 
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Figure 34. Correlations between negative symptoms and (a) adenosine, (b) ADA and (c) 
inosine in CSF and plasma. 
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7.4 DISCUSSION 
In this chapter, we tested the relationship between the adenosine signaling indices and SZ 
symptomatology. We used BPRS-P and SAPS as positive symptom scales, BPRS-N and SANS 
as negative symptom scales, and the GAS as a measure of global functioning.  Testing 
relationship between cognitive symptoms and adenosine signaling was beyond the scope of 
this study. Results yield interesting information which had not been reported in previous 
literatures. 
In the FEANS group, significant inverse correlations between adenosine and positive 
symptoms supported the adenosine theory. It implied that lower adenosine levels correlate with 
more severe positive symptoms. As expected, ADA was found to correlate positively with 
positive symptoms, meaning that higher ADA activity levels predict more severe positive 
symptoms. In addition, inosine levels also inversely correlate with BPRS-P. Since previous 
studies have established adenosine’s role in regulating dopaminergic signaling (S. Ferré et al. 
1991a, S. Ferré et al. 1991b, Salmi et al. 2005) via ARs, and positive symptoms are closely 
related to the dopaminergic alterations (Davis and Kahn. 1991, Howes and Kapur. 2009), we 
have reason to believe that adenosine signaling deficits may, at least partially contribute to SZ 
positive symptoms through dopaminergic signaling. Adenosine and ADA activity levels also 
successfully predict global functioning assessment scores that reflect the extent to which 
symptoms exist and impair or impede daily functioning. This finding implied that adenosine 
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signaling deficits are associated with the extent to which symptoms impair patient daily 
functioning (including work, school, social and personal self-care). 
 Surprisingly, we didn’t find any significant correlations between adenosine signaling 
and negative symptoms. Negative symptoms has been linked to glutamatergic signaling 
alterations in SZ (Coyle and Tsai. 2004, Farber. 2003). However, since glutamatergic signaling 
was not measured in this dissertation, we are not able to check whether it can be affected by 
adenosine or not. Overall, our findings regard to adenosine signaling and negative symptoms 
did not support the adenosine theory and suggested that adenosine signaling might not directly 
contribute to negative symptoms.  
In the chronically ill, off-treatment SZ group, there were findings similar to those for 
the FEANS group. Adenosine inversely correlated with positive symptoms while 
insignificantly correlated with negative symptoms. The only difference is that significant 
inverse correlations was observed between inosine and positive symptoms for the FEANS 
group, but not for the chronic group. This difference might be caused by the limited sample 
size of the chronic group in comparison with the FEANS group. Also, we did not find 
difference of correlating patterns between CSF analyte levels-symptomatology and plasma 
analyte levels-symptomatology, which divergently validated findings in 2.3.1. 
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7.5 CONCLUSION 
1. Adenosine, inosine and ADA activity levels each significantly correlated with positive 
symptoms in both FEANS and chronic off-treatment SZ group. Also, adenosine and ADA 
significantly correlated with GAS. These findings support the adenosine theory that adenosine 
signaling deficits contribute, at least in part, to SZ symptomatology. 
2. No significant correlation was observed between adenosine signaling and negative 
symptoms, suggesting that adenosine signaling deficits in SZ may not directly contribute to 
negative symptoms. 
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8.0  SUMMARY AND PERSPECTIVE 
Based on all information that were yielded from this dissertation and other literatures, here is 
the proposed model in explaining part of SZ’s pathophysiology (Figure 34): Due to the 
environmental and genetic factors (Tsuang. 2000, Tsuang et al. 2001), oxidative stress level in 
the body was elevated (Boskovic et al. 2011). Accumulated oxidative stress levels led to the 
breakdown of AODS (Othmen et al. 2008, Reddy et al. 2003). As an important component of 
AODS, uric acid level thus was reduced (Yao and Zhou. 2017, Yao et al. 1998). The reduction 
of uric acid levels led to the compensatory response of the purine pathway and the metabolism 
was shifted from adenosine towards uric acid (Yao and Zhou. 2017) and thus the adenosine 
signaling on the other end of the metabolism was compromised and deficits were formed (Cai 
et al. 2017, Cai et al. 2018). Then the inhibitory effect from ARs on DRs in the CNS was 
reduced. Due to the decreased inhibitory effect of adenosine signaling on striatal dopaminergic 
signaling via ARs-DRs interactions, striatal dopaminergic signaling was increased (Ferré et al. 
1994). Increased dopaminergic signaling in the striatal region resulted in positive symptoms of 
SZ, which have been illustrated by numerous literatures (Davis and Kahn. 1991, Howes and 
Kapur. 2009). On the other hand, increased oxidative stress led to increased lipid peroxidation 
on cell membranes (Khan et al. 2002, Herken et al. 2001). As adenosine signaling decreased, 
the A1R’s up-regulation on insulin activity through cAMP-dependent protein kinase pathway 
was also diminished (Koupenova et al. 2013). Thus the inhibitory effect of insulin on 
membrane PLA2 activity through phosphoinositide 3-kinases pathway was weakened (Thong 
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et al. 2007, Eichhorn et al. 2001). Consequently, lipolysis rate through membrane PLA2 was 
increased (Zhou et al. 2017, Zhou et al. 2018). Increased lipolysis and lipid peroxidation on 
cell membranes result in membrane defects and eventually caused positive symptoms and 
impaired global functioning. Current front-line treatments for SZ, including first- and second-
generation antipsychotics, were mainly designed to block D2 receptors, and thus explained that 
most positive symptoms are responsive to the current front-line antipsychotics while negative 
and cognitive symptoms are not. In this dissertation, we also noticed that current antipsychotics 
cannot fully normalize the disrupted adenosine signaling in SZ, which may contribute to the 
weakness of current antipsychotics in treating refractory symptoms in SZ patients.  
Findings in this dissertation supported this model by providing several important 
evidence. First, we observed increased oxidative stress levels and increased lipid peroxidation 
in SZ patients in section 4.3.5. Decreased total antioxidant status and uric acid levels in the 
plasma were observed in section 4.3.1 and 4.3.5, suggesting a possible breakdown of AODS in 
SZ pathology. Second, in section 2.3.2, 2.3.3 and 2.3.5, we observed significantly reduced 
levels of adenosine in SZ patients from both plasma and CSF samples. Also, we observed 
significantly decreased inosine and significantly increased ADA activity levels in the CSF 
samples in SZ patients. This finding suggested that adenosine signaling deficits might present 
in SZ patients. Third, section 4.3.1, 4.3.2 and 4.3.3 supported the model by showing a 
homeostatic imbalance of purine pathway in SZ patients. Fourth, membrane defects and striatal 
hyperdopaminergia were partially supported and significantly correlated with adenosine levels 
based on findings in chapter 5 and chapter 6. Fifth, from section 7.3.1 and 7.3.2, we observed 
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significant associations between positive symptoms and analytes (adenosine, inosine and 
ADA). We also observed significant associations between global functions and these analytes. 
This proposed model may help us to better understand SZ’s pathophysiology and point 
out the clinical significance of adenosine signaling in diagnosing and treating SZ patients. First, 
based on findings, plasma and CSF adenosine level can serve as important biomarker and 
therapeutic indicator of SZ. However, plasma ADA and inosine levels cannot serve as 
biomarkers and therapeutic indicators of SZ due to increased variance and noisiness in the 
peripheral tissues. For the CSF samples, despite significant correlations between CSF and 
plasma analyte levels were observed in most cases, levels of ADA and inosine in the CSF were 
observed having less variance and significantly different with those in controls. Also, it was 
observed that levels of ADA and inosine in the CSF could be significantly affected by 
antipsychotics. It is speculated that SZ mainly affects adenosine signaling in the CNS and 
antipsychotics can normalize adenosine signaling more in the CNS than in peripheral tissues. 
Therefore, ADA activity and inosine levels in the CSF can still serve as biomarkers and 
therapeutic indicators of SZ. Second, findings suggested that adenosine signaling modulator 
might be the silver lining in the development of new generation of antipsychotics. 
There are still a lot need to be studied in this area. This dissertation is standing on the 
theoretical foundation of the adenosine theory (Boison et al. 2012, Lara et al. 2006). Based on 
our observations, the biggest concern comes from the relationship between adenosine signaling 
and SZ negative symptoms. Based on adenosine theory, adenosine signaling should at least 
partially correlate with negative symptoms. However, we didn’t observe significant 
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correlations between adenosine signaling and any negative symptom scale scores in either 
FEANS or chronic off-treatment SZ group. The adenosine theory claimed that adenosine 
signaling connected to negative symptoms through glutamatergic signaling with interactions 
between ARs-NMDARs (Tebano et al. 2005, Sebastião et al. 2000, Nörenberg et al. 1997). 
Since we did not measure metabolites in glutamate pathway in this dissertation, more studies 
are needed to illustrate the relationship between these two pathways. 
Besides glutamatergic signaling, serotonin theory is also an important component in 
interpreting SZ’s pathology. However, there is few paper explored the relationship between 
serotonin and adenosine signaling. Actually, serotonin receptors have not been fully studied 
yet. Basic molecular pharmacology data is needed to support the serotonin theory of SZ.  
Another interesting topic to study is the cognitive symptoms in SZ. Since we did not 
have cognitive symptoms scale data on hand, it would be interesting to link adenosine signaling 
to cognitive symptoms in SZ.  
Overall, adenosine signaling and purine metabolism seem to have long been overlooked 
in the SZ research. As adenosine theory further develops and more clinical studies that focusing 
on it will be carrying out during these years, more and more promising findings are expected 
to come out in the near future. 
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Abbreviation: PLA2 = phospholipase A2. 
Figure 35. Postulated model of adenosine signaling in the SZ pathophysiology. 
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